Tasks, reference findings and scored hypotheses of the generation benchmark

Pro-inflammatory cytokines enriched in aged plasma, particularly IL-6 and TNF-α, act on intestinal stem cells (ISCs) to suppress mitochondrial oxidative phosphorylation and thereby reduce regenerative capacity. Neutralizing these cytokines in aged systemic circulation should restore ISC metabolic and regenerative function. Mechanism: Aged circulating IL-6/TNF-α engage JAK/STAT and NF-κB in ISCs, downregulating mitochondrial biogenesis and electron-transport chain activity and shifting cells toward a less regenerative metabolic state. Prediction: Heterochronic exposure of young ISCs to aged serum will impair OCR and organoid-forming efficiency in an IL-6/TNF-dependent manner; cytokine blockade or genetic ablation of cognate receptors in ISCs will rescue metabolism and regeneration without requiring changes in other aged plasma components.

• GPT-5.6 Solmatch score 3compatible with the reference findingplausibility 4 of 5

  It captures the central role of aged circulating inflammation, including TNF, in suppressing ISC mitochondrial activity and regeneration, and predicts rescue by cytokine or receptor blockade. However, it dilutes the specific TNF–TNFR1–fatty-acid-oxidation mechanism with IL-6/JAK–STAT, does not identify epithelial TNFR1 specifically, and omits mitochondrial fusion.

• Claude Opus 5.5match score 4compatible with the reference findingplausibility 5 of 5

  Names TNF-α (alongside IL-6) in aged circulation as the causal factor suppressing ISC mitochondrial metabolism and regeneration, with receptor-level blockade as rescue — the central causal claim. It is vaguer on epithelial TNFR1 specificity and on fatty acid oxidation/mitochondrial dynamics (emphasizing OXPHOS/biogenesis instead), and dilutes TNF with an equal IL-6 claim.

• Gemini 4 Argon (medium)match score 4compatible with the reference findingplausibility 5 of 5

  P1 accurately identifies circulating TNF-α acting via its cognate epithelial receptor on ISCs to suppress mitochondrial metabolism and regeneration, as well as the rescue via cytokine blockade or receptor ablation. It misses the specific emphasis on fatty acid oxidation and mitochondrial fusion, and pairs TNF-α with IL-6.

Age-rising plasma CXCL9, produced mainly by non-senescent interferon-responsive endothelium and tissue macrophages, is a causal circulating driver of tissue ageing acting through CXCR3 on endothelial cells and mesenchymal progenitors, where CXCR3–Gi–PI3Kgamma–AKT–mTORC1 signalling drives an mTOR-dependent senescence-like arrest and loss of angiogenic capacity, making CXCL9 an initiator rather than merely the best cross-tissue biomarker of inflammaging. Mechanism: Low-grade type-II interferon tone from age-accumulating effector-memory T cells induces STAT1-dependent CXCL9 in endothelium and macrophages, independently of local senescent-cell SASP. Secreted CXCL9 binds CXCR3-B/CXCR3-A heterodimers on recipient endothelial cells and PDGFRb+ progenitors; Gi-coupled PI3Kgamma activates AKT and raises mTORC1, which simultaneously (i) suppresses autophagic flux through ULK1-S757 phosphorylation, allowing damaged-mitochondria and lipofuscin accumulation, and (ii) amplifies translation of p21 and SASP transcripts via 4E-BP1 release and the MK2–ZFP36L1 axis. CXCR3-B signalling additionally engages a Gs/PKA–ERK-low program that represses VEGFR2-driven angiogenesis, producing capillary rarefaction; rarefaction then lowers tissue oxygen and nutrient delivery, which is the metabolic arm (muscle and adipose insulin resistance from reduced perfusion rather than from direct receptor interference). Prediction: Adult-onset endothelial-specific Cxcr3 deletion in 18-month-old mice restores capillary density and lowers p16/p21 in heart and skeletal muscle and improves exercise capacity, while myeloid-specific deletion does not; and infusion of recombinant CXCL9 into young mice at measured old-plasma concentrations for 8 weeks reproduces capillary rarefaction and endothelial senescence, an effect abolished by low-dose rapamycin or by endothelial Rptor deletion — placing causality on mTORC1 downstream of CXCR3. Decisive against a SASP-output interpretation: plasma CXCL9 stays elevated after senolytic clearance (D+Q or INK-ATTAC) but falls after IFN-gamma neutralisation or T-cell depletion, and CXCL9 rise precedes detectable p16 accumulation in the same tissues on a longitudinal time course.

• GPT-5.6 Solmatch score 3compatible with the reference findingplausibility 2 of 5

  It reproduces part of the relevant AKT–mTOR pro-senescence pathway but assigns activation to CXCL9–CXCR3 in different cell types and omits ANGPTL8, direct AKT2 binding, S6K, and Angptl8 longevity genetics. CXCL9 is strongly associated with ageing, but the proposed receptor isoforms, PI3Kγ coupling, and direct mTOR-driven senescence mechanism are weakly established and potentially species-dependent.

• Grok 4.7match score 2compatible with the reference findingplausibility 3 of 5

  CXCL9–CXCR3–PI3Kγ–AKT–mTORC1 belongs to the same AKT–mTOR senescence class while naming a different ligand, an indirect GPCR route, and an endothelial/progenitor focus rather than direct ANGPTL8–AKT2 binding in adipocytes; both can be true. CXCL9 is a documented inflammaging chemokine, but physiological CXCR3–PI3Kγ–mTORC1 as an initiating senescence program is speculative.

• Gemini 4 Argon (medium)match score 2compatible with the reference findingplausibility 4 of 5a suitable alternative mechanism

  Identifies a different circulating ligand and target cell (CXCL9–CXCR3 in endothelium), but shares the downstream AKT–mTORC1 signaling axis as the intracellular driver of senescence. It is a credible, testable hypothesis grounded in known inflammaging biology and is compatible with ANGPTL8 acting via AKT2–mTOR in adipocytes.

A conserved, proteolytically liberated bacterial peptide (corisin, derived from bacterial transglycosylases of IPF-enriched Staphylococcus and Streptococcus species) directly initiates idiopathic pulmonary fibrosis de novo by inducing mitochondrial dysfunction in alveolar type II (AT2) cells, simultaneously driving caspase-dependent apoptosis, p53/p21-mediated senescence, and TGF-beta1-dependent epithelial-to-mesenchymal phenotypic transition. Mechanism: Extracellular bacterial or host serine proteases cleave a conserved 19-amino-acid peptide motif (corisin) from surface-associated bacterial transglycosylases. Upon internalization or membrane interaction with AT2 stem/progenitor cells, the peptide disrupts mitochondrial outer membrane integrity and suppresses PINK1-dependent mitophagy—an effect amplified in aged lungs with baseline mitochondrial vulnerability. Cells experiencing severe mitochondrial depolarization undergo cytochrome c release and intrinsic caspase-9/caspase-3 apoptosis, depleting the regenerative stem cell pool. Concurrently, surviving AT2 cells exposed to sub-lethal mitochondrial ROS and oxidative DNA damage activate the ATM-p53-p21CIP1/p16INK4a senescence cascade and undergo TGF-beta1/Smad2/3- and Snail/Slug-driven epithelial-to-mesenchymal transition (EMT) as well as arrest in a KRT8+/KRT17+ transitional state. These senescent transitional cells secrete a profibrotic SASP (TGF-beta1, IL-6, PAI-1, CTGF) and upregulate alpha-v-beta-6 integrin to cleave latent TGF-beta1, activating resident fibroblasts into apoptosis-resistant alpha-SMA+ myofibroblasts and initiating a self-sustaining mechanotransductive (YAP/TAZ) fibrotic loop. Prediction: Repeated intratracheal instillation of synthetic corisin—or mono-colonization with wild-type Staphylococcus nepalensis, but not an isogenic mutant carrying a non-cleavable transglycosylase motif—into uninjured aged or germ-free mice will independently induce AT2 caspase-3 apoptosis, p21+/SA-beta-gal+ cellular senescence, loss of E-cadherin with acquisition of vimentin/KRT8+/KRT17+ transitional markers, and progressive architectural honeycombing and collagen deposition; furthermore, systemic or inhaled administration of a monoclonal anti-corisin neutralizing antibody will halt progression without requiring broad-spectrum antibiotics.

• GPT-5.6 Solmatch score 3compatible with the reference findingplausibility 3 of 5

  It correctly identifies corisin as the causal bacterial peptide and predicts apoptosis, senescence, epithelial phenotypic transition, and progressive fibrosis, but replaces the demonstrated proteasome mechanism with an unsupported mitochondrial and mitophagy mechanism and omits the decisive lavage-depletion and constitutive-expression evidence. Its central claim is supported by the finding, while most downstream molecular details remain conjectural.

• Grok 4.7match score 3compatible with the reference findingplausibility 5 of 5

  Corisin is correctly identified as sufficient for AT2 apoptosis, senescence, EMT, and progressive fibrosis, including a mitochondrial step, but the stated driver is outer-membrane injury and failed PINK1 mitophagy, omitting proteasome activation and BALF depletion. Mitochondrial stress can accompany enhanced ubiquitin-proteasome activity, and the peptide-centered claim is specific and well grounded in corisin and epithelial cell-fate biology.

• Claude Opus 5.5match score 4compatible with the reference findingplausibility 5 of 5

  Names corisin itself, its transglycosylase origin and Staphylococcus nepalensis source, and the full apoptosis/senescence/EMT/progressive fibrosis outcome with neutralizing-antibody rescue; it misses the proteostasis/proteasome-enhancement mechanism, substituting mitochondrial dysfunction and mitophagy suppression, which is adjacent to the reported mitochondrial localization rather than contradictory.

Mild energetic stress preserves proteostasis and extends C. elegans lifespan by activating an AAK-2–HLH-30 transcriptional program that restores lysosomal degradative capacity. Increased lysosomal acidification, rather than increased autophagosome formation alone, is the limiting causal step. Mechanism: AMP-activated protein kinase AAK-2 reduces TORC1 signaling, promoting nuclear accumulation of HLH-30 and expression of lysosomal acidification and proteolysis genes. Acidic, protease-active lysosomes complete degradation of damaged proteins delivered by autophagy. Prediction: Adult-specific attenuation of HLH-30-dependent lysosomal acidification abolishes stress-induced cargo degradation and lifespan extension despite maintained autophagosome production. Constitutively nuclear HLH-30 bypasses AAK-2 loss but fails to restore benefits when lysosomal acidification remains impaired.

• Grok 4.7match score 3compatible with the reference findingplausibility 5 of 5

  Lysosomal degradation of damaged proteins under energetic stress is the same effector process that links mild stress to proteostasis and lifespan, with AAK-2/TORC1 and HLH-30-dependent acidification in place of intestinal ELT-2, residue R249, and CPR-5/CPR-8. Acidification can be required together with those proteases, and AMPK–HLH-30 control of lysosomes is a strong, specific account.

• Claude Opus 5.5match score 3compatible with the reference findingplausibility 4 of 5

  Correctly identifies that the limiting step is a transcriptionally restored lysosomal degradative capacity acting on damaged proteins, but attributes it to AAK-2/TORC1/HLH-30 and acidification rather than intestinal ELT-2 directly activating cathepsin genes (CPR-5/CPR-8), and names energetic rather than mitochondrial-respiration stress; the two programs could operate in parallel.

• Gemini 4 Argon (medium)match score 2compatible with the reference findingplausibility 5 of 5a suitable alternative mechanism

  P4 identifies the same broad mechanism class—metabolic/energetic stress in C. elegans transcriptionally boosting lysosomal degradative and proteolytic capacity to clear damaged proteins—but attributes it to AAK-2/HLH-30 and lysosomal acidification rather than ELT-2 and CPR-5/CPR-8. It is compatible alongside the ELT-2 pathway and is strongly supported by known AMPK/TFEB (HLH-30) biology.

Physical activity delays ovarian ageing by improving systemic insulin sensitivity and elevating adiponectin, which lowers ovarian insulin/IGF-1 receptor signalling, dampens PI3K–Akt–mTOR hyperactivation in primordial follicles, and slows reserve exhaustion and endocrine decline. Mechanism: Activity → reduced hyperinsulinaemia and increased adiponectin → decreased ovarian IR/IGF1R–PI3K–Akt–mTOR tone (with optional adiponectin-receptor–AMPK contribution) → restrained primordial activation and granulosa stress → preserved follicle quantity, AMH and cyclicity → extended reproductive lifespan. Causality runs through metabolic correction of local growth-factor signalling rather than myokine delivery alone. Prediction: Exercise fails to preserve primordial counts or AMH when ovarian IR/IGF1R–mTOR signalling is locked high (ovary-conditional gain-of-function or constitutive mTOR activation), even if irisin and systemic AMPK rise normally; adiponectin-receptor agonists or insulin-sensitisers without exercise slow follicle depletion only when ovarian p-Akt/p-S6 fall—discriminating this metabolic axis from irisin–PGC-1α and direct ovarian AMPK/SIRT1/FOXO3a mechanisms.

• GPT-5.6 Solmatch score 3compatible with the reference findingplausibility 4 of 5

  It correctly identifies increased adiponectin as a mediator of exercise-induced ovarian protection and anticipates benefit from adiponectin-receptor agonism, but shifts the central mechanism to reduced insulin/IGF-1–mTOR signaling and does not state the adiponectin-deficiency result or AdipoRon's demonstrated reproductive-lifespan effect. The proposed metabolic pathway is credible and testable.

• Claude Opus 5.5match score 3compatible with the reference findingplausibility 4 of 5

  Names elevated adiponectin as part of the exercise mechanism and includes an adiponectin-receptor–AMPK contribution plus an AdipoRon-style agonist prediction, so it hits the right target, but adiponectin is framed as secondary to insulin/IGF-1–PI3K–Akt–mTOR correction rather than as the ovarian effector, and it misses the deficiency-attenuation and reproductive-lifespan specifics.

• Gemini 4 Argon (medium)match score 3compatible with the reference findingplausibility 5 of 5

  Correctly identifies elevated adiponectin and the efficacy of adiponectin-receptor agonists in delaying ovarian ageing and extending reproductive lifespan, though it co-emphasizes systemic insulin/IGF-1/mTOR suppression and does not explicitly state the necessity experiment in adiponectin-deficient mice.

[SCOUT 2] SOD1G93A motor neurons are prematurely eaten alive by microglia (primary phagoptosis) and executed by non-apoptotic ferroptosis because early depletion of glutathione peroxidase 4 (GPX4) and accumulation of oxidized phosphatidylethanolamines cooperate with sub-lethal Ca2+ transients to inactivate the aminophospholipid flippase ATP11C and activate the scramblase ANO6 (TMEM16F), locking phosphatidylserine onto the outer plasma membrane leaflet of viable neurons. Blocking outer-leaflet phospholipid scrambling, microglial MerTK/C1q phagocytic receptors, or lipid peroxidation rescues viable motor neurons from live cannibalism and ferroptotic lysis. Mechanism: [SCOUT from Erythrocyte Senescence Hematology & Splenic Macrophage Eryptosis] In hematology, senescent or oxidatively stressed red blood cells lack nuclei and apoptotic caspases yet are rapidly cleared alive by splenic red-pulp macrophages because sub-lethal Ca2+ spikes and lipid hydroperoxides inhibit the P4-ATPase flippase ATP11C and activate the Ca2+-dependent phospholipid scramblase ANO6 (TMEM16F), exposing phosphatidylserine (PS) on the exoplasmic leaflet for opsonization by Gas6, MFG-E8, and C1q. Applying this hematological clearance mechanism to ALS resolves why genetic ablation of canonical necroptosis (Ripk3-/- or Mlkl-/-; Wang et al., 2020) and caspase inhibitors fail to save SOD1G93A motor neurons in vivo. In SOD1G93A motor neurons, early selective downregulation of selenoprotein GPX4 (Chen et al., 2015; Wang et al., 2022) allows polyunsaturated phosphatidylethanolamine hydroperoxides (oxPEs) to accumulate in the plasma membrane. Membrane peroxidation and sub-threshold Ca2+ influx activate neuronal ANO6 (TMEM16F; Soule et al., 2019) while oxidative ATP depletion stalls ATP11C flippase error-correction. Consequently, stressed but metabolically recoverable motor neurons display persistent outer-leaflet PS and oxPEs, which recruit complement C1q/C3/C5aR1 (Lee et al., 2017) and bridging molecules (Gas6/MFG-E8) to trigger microglial MerTK/AXL-mediated engulfment of live motor neurons (primary phagoptosis), while un-engulfed neurons succumb to iron-dependent ferroptotic membrane rupture. Prediction: Longitudinal in vivo two-photon fluorescence lifetime imaging (2P-FLIM) via chronic spinal cord windows in SOD1G93A mice using the reversible PS biosensor pSIVA and the ATP/ADP sensor PercevalHR will capture microglia actively engulfing pSIVA-positive motor neuron somata that still possess intact mitochondrial membrane potential and recoverable ATP/ADP ratios; furthermore, double genetic ablation of neuronal Ano6 and microglial Mertk (or neuronal GPX4 overexpression) will prevent live neuronal engulfment and extend survival significantly more than pan-caspase or RIPK1/RIPK3 genetic ablation.

• GPT-5.6 Solmatch score 5compatible with the reference findingplausibility 2 of 5

  It includes live microglial phagocytosis driven by exposed neuronal phosphatidylserine through Axl/MerTK and predicts neuronal, synaptic, and survival rescue. Its added GPX4–ATP11C–ANO6–ferroptosis chain is highly speculative and presents several unestablished steps as causal.

• Grok 4.7match score 4compatible with the reference findingplausibility 3 of 5

  It identifies live microglial AXL/Mer engulfment of phosphatidylserine-exposing motor neurons as what removes them and shortens survival, with neuromuscular-synapse preservation left implicit. The added ferroptotic-lysis arm and the GPX4–ATP11C–ANO6 scrambling cascade are speculative extensions of that core.

• Claude Opus 5.5match score 5compatible with the reference findingplausibility 4 of 5

  States that microglia eat living SOD1G93A motor neurons via MerTK/AXL recognition of externalized phosphatidylserine, and that blocking this rescues neurons and extends survival — all key points present; the added ferroptosis/ANO6/GPX4 execution layer is extra detail that does not contradict the finding.

Progerin depletes H3K9me3 and HP1 at lamina-associated domains, derepressing normally silent inflammatory and senescence gene clusters and thereby driving premature senescence. Restoring H3K9 methylation (for example by boosting SUV39H1 activity or inhibiting H3K9 demethylases) will reinstate heterochromatin, dampen SASP, and prolong survival. Mechanism: Loss of constitutive heterochromatin (H3K9me3/HP1) directly derepresses senescence and SASP loci. Prediction: Genome-wide H3K9me3 ChIP-seq will show selective loss at SASP and inflammatory loci preceding senescence marker induction, and H3K9me3 restoration will reverse those expression changes without requiring reduced DNA damage signaling.

• GPT-5.6 Solmatch score 3compatible with the reference findingplausibility 4 of 5

  It correctly centers loss of HP1-associated heterochromatin and consequent derepression of inflammatory or SASP loci, placing it closest to the published core mechanism. It nevertheless omits HMGA1 recruitment of USP7, HP1β stabilization, ANGPTL2, HP1β dependence, and UHP, and proposes H3K9 methylation as a different intervention.

• Claude Opus 5.5match score 3compatible with the reference findingplausibility 4 of 5

  Correctly centres HP1/H3K9me3 heterochromatin loss derepressing SASP/inflammatory loci as the link to senescence, which is the right core mechanism class and target layer, but misses HMGA1, USP7-mediated HP1β stabilization, the specific ANGPTL2 node and the peptide/lifespan result, and proposes a methyltransferase/demethylase route rather than HP1β protein stability.

• Gemini 4 Argon (medium)match score 3compatible with the reference findingplausibility 5 of 5

  P5 correctly identifies the loss of HP1-associated heterochromatin and the resulting derepression of silent SASP/senescence loci as the core mechanism, though it focuses on H3K9me3 methyltransferases/demethylases and misses the specific HMGA1–USP7–HP1β stabilization axis and ANGPTL2 target. It is fully compatible with the published finding and strongly supported by established HGPS biology.

A single master regulator whose expression rises with age — a megakaryocyte-promoting transcription factor/RNA-binding regulator (e.g. FLI1, or an age-induced miRNA such as miR-125a/b acting on erythroid targets) — is the causal node connecting aged transcriptional remodeling to lineage imbalance. Mechanism: Age-elevated regulator directly activates megakaryocyte enhancer networks and post-transcriptionally destabilizes erythroid determinants (KLF1/GATA1 cofactors), so its dose alone sets the erythroid:platelet split. Prediction: Knockdown of the candidate regulator in aged HSPCs should normalize erythroid:platelet ratios without altering clonal composition, inflammation, or global methylation, while its forced overexpression at aged levels in young HSPCs should produce the aged phenotype — dose-dependent and sufficient, distinguishing it from the permissive mechanisms above.

• GPT-5.6 Solmatch score 3compatible with the reference findingplausibility 4 of 5

  It correctly posits a master regulatory node that suppresses erythroid determinants and promotes platelet-lineage output, but it does not identify Pbx1 or direct repression of Gata1 and instead suggests different regulators. The dose-dependent perturbation framework is biologically credible and strongly testable.

• Grok 4.7match score 3compatible with the reference findingplausibility 4 of 5

  A single age-elevated intrinsic regulator that is necessary and sufficient to suppress erythroid output through the GATA1 pathway matches the core architecture of a Pbx1 hub, while the named nodes (FLI1 or miR-125) and the post-transcriptional mechanism miss Pbx1’s repression of Gata1. Those regulators can still act in parallel with Pbx1, and both have credible, testable links to hematopoietic fate.

• Gemini 4 Argon (medium)match score 3compatible with the reference findingplausibility 5 of 5

  Correctly identifies the core mechanism class—an age-upregulated intrinsic master transcription factor that suppresses GATA1-related erythroid determinants to drive the erythroid-to-platelet shift—but misses Pbx1 as the specific regulator and focuses on FLI1 or miR-125a/b instead. It is highly plausible and compatible with Pbx1 acting in the same regulatory network.

Age-related downregulation of the mechanosensitive cation channel Piezo1 in cortical osteocytes and osteoprogenitors blunts load-induced Ca2+ influx, preventing the coordinated activation of bone formation and suppression of bone resorption. Targeted pharmacological stimulation of residual Piezo1 channels with a small-molecule agonist (such as Yoda1) lowers the mechanical activation threshold and restores the anabolic response of aged cortical bone to mechanical loading. Mechanism: In young cortical bone, fluid shear stress and matrix deformation open membrane Piezo1 channels in osteocytes and periosteal osteoprogenitors, driving rapid intracellular Ca2+ influx that activates CaMKII, Akt, Calcineurin/NFAT1/c-Jun, and YAP/TAZ nuclear translocation. This cascade upregulates osteogenic Wnt1 and Cyr61, represses osteocytic Sost (sclerostin), and increases the OPG/RANKL (Tnfrsf11b/Tnfsf11) ratio to couple periosteal bone formation with restraint of endocortical osteoclastogenesis. With aging, reduced Piezo1 abundance raises the mechanical strain threshold required to trigger sufficient Ca2+ entry under physiological loading. Sub-saturating allosteric stimulation with Yoda1 stabilizes the open conformation of remaining Piezo1 channels during mechanical strain, restoring mechanosensitive Ca2+ oscillations, YAP/TAZ and Wnt1 activation, Sost suppression, and net cortical bone gain. Prediction: In aged mice subjected to non-invasive axial tibial loading, co-administration of a low-dose Piezo1 agonist (Yoda1) that has minimal baseline effect in non-loaded limbs will synergistically restore load-induced in vivo osteocytic Ca2+ influx, Wnt1 expression, Sost suppression, and periosteal mineral apposition rate, whereas osteocyte/osteoblast-specific deletion of Piezo1 (Dmp1-Cre or Col1a1-Cre) will completely abolish this rescue even when downstream canonical Wnt signaling remains inducible.

• GPT-5.6 Solmatch score 3compatible with the reference findingplausibility 4 of 5

  It correctly identifies Piezo1 activation during loading as the intervention that restores aged cortical bone anabolism and includes sclerostin suppression and reduced resorption. However, it replaces the defining connexin 43–PI3K–Akt–hemichannel–PGE2 mechanism with a largely Ca2+–YAP/Wnt pathway.

• Grok 4.7match score 3compatible with the reference findingplausibility 5 of 5

  Piezo1, the need for concurrent loading, sclerostin suppression, and a formation-over-resorption cortical response match the finding, but the stated mechanism is Ca2+/YAP/Wnt rather than Piezo1–connexin 43 co-localization, PI3K-Akt opening of hemichannels, and PGE2. Piezo1–Ca2+ mechanotransduction is well supported and can operate alongside hemichannel signaling.

• Claude Opus 5.5match score 4compatible with the reference findingplausibility 5 of 5

  Captures the central claim: aged bone's blunted anabolic response reflects insufficient Piezo1 mechanosignaling, and co-applying a Piezo1 agonist with loading restores cortical formation, with sclerostin suppression and shifted formation/resorption balance; it misses the connexin 43 hemichannel/PGE2 arm, routing instead through YAP/TAZ–Wnt1, though it does include Akt.

Excessive calcium transfer from the endoplasmic reticulum to mitochondria drives senescence through mitochondrial oxidant production. This mechanism links disturbed calcium homeostasis to persistent nuclear DNA damage. Mechanism: Sustained IP3 receptor–GRP75–VDAC coupling increases mitochondrial calcium uptake through MCU. Calcium overload disrupts electron transport, increasing hydrogen peroxide delivery to the nucleus and activating DNA damage checkpoints. Prediction: Following a defined calcium-homeostasis perturbation, partial MCU inhibition should prevent mitochondrial calcium overload, nuclear oxidative lesions, and senescence without correcting endoplasmic-reticulum stress. Restoring nuclear hydrogen peroxide experimentally should bypass this protection.

• Grok 4.7match score 3compatible with the reference findingplausibility 4 of 5

  Calcium overload and mitochondrial dysfunction leading to a nuclear DNA-damage response and senescence match the core downstream pathway, but the hypothesis omits DHCR24 and ENKUR and treats ER stress as dispensable in favor of IP3R–MCU-dependent hydrogen peroxide. That more specific route is not refuted by the finding and is a credible, testable account of calcium-linked senescence.

• Claude Opus 5.5match score 3compatible with the reference findingplausibility 4 of 5

  Captures the ER-to-mitochondria calcium overload step driving organelle dysfunction and nuclear DNA damage, matching the middle of the published axis, but omits the DHCR24-ENKUR upstream trigger and attributes damage to MCU-dependent oxidants rather than ATM activation downstream of combined ER/mitochondrial stress; MAM calcium transfer and mitochondrial ROS are well-established.

• Gemini 4 Argon (medium)match score 3compatible with the reference findingplausibility 5 of 5

  This hypothesis accurately captures the core downstream physiological pathway linking calcium overload, endoplasmic-reticulum stress, and mitochondrial dysfunction to nuclear DNA damage and senescence, though it misses the upstream DHCR24-ENKUR regulators and specifies IP3R-GRP75-VDAC/MCU instead. It is well-supported by established biology and fully compatible with the published finding.

Circulating bioactive sphingolipids and oxidized lipoprotein species—specifically long-chain ceramides (such as C16:0 and C24:1 ceramides) and oxidized LDL that inflect upward during midlife—act as causal metabolic drivers of endothelial and stromal cell senescence, whose deleterious cellular effects are reversible through inhibition of sphingolipid synthesis or enhanced lipid clearance. Mechanism: Excess circulating ceramides and oxidized lipoproteins are internalized via CD36 and scavenger receptors into vascular endothelial, hepatic, and mesenchymal progenitor cells, where they integrate into mitochondrial membranes to disrupt electron transport chain complex III/IV activity and activate protein phosphatase 2A (PP2A) and p38 MAPK. This inhibits Akt/eNOS signaling, triggers persistent mitochondrial ROS production, and stabilizes p53/p21CIP1 to enforce premature vascular and metabolic senescence. Prediction: Fractionating aged human plasma will show that lipid-depleted plasma loses a substantial fraction of its pro-senescent activity on cultured human endothelial cells while purified aged ceramide fractions reproduce it; furthermore, pharmacological inhibition of serine palmitoyltransferase or dihydroceramide desaturase (DES1) in aged animals will restore endothelial nitric oxide production and clear vascular senescence markers.

• GPT-5.6 Solmatch score 3compatible with the reference findingplausibility 4 of 5

  It closely overlaps the finding through causal lipoprotein-driven endothelial senescence and a reversible metabolic burden, but substitutes oxidized LDL and ceramides for the reported LDL, triglycerides, glucose, uric acid and tumor markers. The proposed oxidative, mitochondrial and Akt/eNOS mechanisms are biologically credible and experimentally testable.

• Grok 4.7match score 3compatible with the reference findingplausibility 4 of 5

  Oxidized LDL and ceramides match the core of an age-linked lipoprotein burden that causes endothelial senescence and is reversible, while omitting glucose, uric acid, CEA, HE4 and dietary reversal in favor of sphingolipid-enzyme blockade. Those lipids can act together with the reported analytes, and ceramide and oxidized-LDL endothelial toxicity is established biology with a direct experimental test.

• Claude Opus 5.5match score 3compatible with the reference findingplausibility 4 of 5

  Overlaps substantially: lipid species including oxidized LDL as causal drivers of endothelial senescence, tested on human endothelial cells, with reversibility via lipid-lowering — but it narrows to ceramides/oxLDL and omits glucose, uric acid, the tumor markers and the sex-divergent midlife trajectory.

SCOUT (bioelectronic medicine / sensory neurophysiology). The metabolite's receiver is neural, not immune: it acts on mucosal vagal and spinal afferent terminals, and suppression of inflammaging is relayed systemically by the cholinergic anti-inflammatory reflex. No immune cell in the gut needs to see the molecule at all. Mechanism: Luminal metabolites depolarise enterochromaffin cells and directly sensitise vagal afferent terminals; afferent traffic through the nodose ganglion and NTS drives efferent vagal output and splenic/α7nAChR-dependent restraint of myeloid TNF production. Age degrades this arc (afferent sensitivity, nodose neuron loss, reduced efferent tone), which explains the P3 failure mode as a neural rather than receptor-pharmacological lesion: the molecule is delivered, the epithelium is intact, and the wire is cut. It also predicts that benefit appears in distant tissues (spleen, liver, brain) faster than local gut cytokines change — a latency signature no local-immunomodulation model produces. Prediction: Subdiaphragmatic vagotomy, nodose-ganglion chemogenetic silencing, or α7nAChR knockout abolishes the strain's and the metabolite's effect on systemic IL-6, frailty and vaccine-independent healthspan endpoints, while gut-local epithelial integrity measures still improve. Conversely, electrical or ultrasonic vagus stimulation at matched afferent firing rate SUBSTITUTES for the microbe entirely in old germ-free or antibiotic-treated mice — benefit with no organism and no metabolite. Supporting kinetics: afferent firing and splenic cytokine suppression precede any change in luminal metabolite steady state by hours. This separates neural relay from direct immunoreceptor signalling (GPR/AhR models), which predict vagotomy-insensitive benefit.

• GPT-5.6 Solmatch score 3compatible with the reference findingplausibility 3 of 5

  It accepts that the bacterium and its metabolite can suppress systemic inflammation and improve function, but proposes an unreported neural receptor pathway and omits the specific organism, 5-AVAB identity and age-related depletion. Microbiota–vagus signalling and the cholinergic anti-inflammatory reflex are established, though direct 5-AVAB activation of this circuit remains speculative.

• Grok 4.7match score 2compatible with the reference findingplausibility 4 of 5a suitable alternative mechanism

  Systemic suppression is attributed to vagal afferent sensing and the cholinergic anti-inflammatory reflex, which can sit downstream of B. pseudocatenulatum and 5-AVAB. It does not identify the organism, the age-related depletion, or 5-AVAB. The reflex is established physiology and the vagotomy and stimulation tests are specific and credible.

• Gemini 4 Argon (medium)match score 2compatible with the reference findingplausibility 4 of 5a suitable alternative mechanism

  P4 does not identify B. pseudocatenulatum or 5-AVAB, instead proposing a downstream neuro-immune relay via vagal afferents and the cholinergic anti-inflammatory reflex to explain how a gut metabolite suppresses systemic inflammaging. This is compatible with the published summary (especially since it allows that gut-local epithelial measures still improve) and represents a credible, testable physiological mechanism.

Chronological aging blunts the initial phase of injury-induced Müller glia (MG)-to-neuron conversion because primed aged microglia and blood-retinal barrier (BRB)-infiltrating myeloid cells transform the acute injury cue from a transient plasticity signal into sustained, anti-neurogenic neuroinflammation. Rather than permitting dedifferentiation, this exaggerated immune response locks injured aged MG into persistent fibrotic gliosis and actively suppresses proneural reprogramming. Mechanism: In young adult retinas, acute damage (such as NMDA excitotoxicity) provides a brief, self-limiting activating signal that primes MG for Ascl1-mediated transdifferentiation. In aged retinas, dystrophic/primed resident microglia and peripheral monocytes entering through a leaky aged BRB hyper-secrete TNF-alpha, IL-1beta, IL-6, and Type I/II interferons upon identical injury. This cytokine surge drives chronic phosphorylation of STAT3, canonical NF-kappaB (p65/RelA), and ISGF3 signaling within MG, which transcriptionally upregulates dominant-negative bHLH inhibitors (Id1, Id3), feedback repressors (Socs3), Notch effectors (Hes1/5), and gliotic cytoskeleton genes (Gfap), thereby neutralizing Ascl1 transcriptional activity even when neurogenic chromatin is rendered accessible by histone deacetylase inhibition (TSA). Prediction: Unlike intrinsic epigenetic models (which predict that aged MG remain refractory to Ascl1 + TSA even in an inflammation-free environment) or late-stage maturation models (which predict normal early neuroblast yields), this hypothesis predicts that depleting microglia/myeloid cells (via CSF1R inhibition with PLX5622) or conditionally ablating Ikkb, Stat3, or Ifnar1 specifically in aged MG prior to NMDA injury will restore early (day 4-7) Ascl1 + TSA-induced neuroblast conversion efficiency and Otx2/Neurod1 induction to young adult levels without requiring additional chromatin-modifying enzymes; conversely, exposing young injured retinas or retinal explants to aged microglial conditioned medium or recombinant TNF-alpha/IFN-beta will phenocopy the aged reprogramming block.

• GPT-5.6 Solmatch score 4compatible with the reference findingplausibility 4 of 5

  It captures the central finding that exaggerated age-associated neuroinflammation prevents progenitor-program activation and maintains reactive Müller glial states. The specific cytokines, infiltrating cells, signaling pathways, and prediction of complete restoration are plausible but go beyond the evidence, and it does not include the demonstrated partial dexamethasone rescue.

• Grok 4.7match score 4contradicts the reference findingplausibility 5 of 5

  This states the central mechanism: an exaggerated injury-evoked myeloid cytokine response drives reactive gliosis and blocks early proneural and progenitor conversion in aged Müller glia. It conflicts with partial dexamethasone rescue, because it predicts that removing that immune signal alone restores young-adult conversion and leaves no glial-intrinsic barrier.

• Claude Opus 5.5match score 4compatible with the reference findingplausibility 4 of 5

  Captures the central causal claim — age-exaggerated retinal neuroimmune/inflammatory signaling blocks MG-to-neuron reprogramming and is reversible by anti-inflammatory intervention — and adds the gliotic/reactive glial state; it only underweights the glia-intrinsic failure to activate progenitor programs by framing inflammation as nearly sufficient.

Experimentally increasing the somatic mtDNA mutation rate via proofreading-deficient DNA polymerase gamma (POLG) in a large mammal directly drives systemic premature ageing and shortens lifespan by exhausting adult stem and progenitor cell pools. This progeroid phenotype arises even without elevated mitochondrial reactive oxygen species (ROS). Mechanism: Accumulation of random point mutations and linear deletions in mtDNA destabilizes respiratory chain complexes I and IV, triggering bioenergetic failure and intrinsic caspase-dependent apoptosis specifically within rapidly dividing somatic stem cell compartments (such as hematopoietic, intestinal, and neural progenitors), thereby impairing tissue regeneration. Prediction: Large mammals engineered with exonuclease-deficient POLG will exhibit early-onset alopecia, kyphosis, anemia, sarcopenia, and reduced lifespan accompanied by severe depletion of tissue-resident stem cells and respiratory chain complex instability, but without a corresponding increase in oxidative macromolecular damage (e.g., 8-oxodG or lipid peroxidation) or rescue by mitochondrial antioxidants.

• GPT-5.6 Solmatch score 4compatible with the reference findingplausibility 5 of 5

  It closely matches the finding by identifying proofreading-deficient POLG, increased somatic mtDNA mutations, systemic progeroid phenotypes, apoptosis and shortened lifespan; only the elevated senescence-marker result is not stated. Respiratory-chain dysfunction, stem-cell depletion and ROS-independent apoptosis form a well-supported, specific and testable mechanism.

• Grok 4.7match score 4compatible with the reference findingplausibility 5 of 5

  It states the central finding: proofreading-deficient POLG raises somatic mtDNA mutations and drives systemic premature ageing, anemia, apoptosis, respiratory-chain failure, and a shorter lifespan without requiring elevated ROS. Senescence-associated markers are not included; stem- and progenitor-cell exhaustion with caspase-dependent apoptosis is the well-supported mutator mechanism and fits the reported phenotypes.

• Claude Opus 5.5match score 5compatible with the reference findingplausibility 5 of 5

  Names exonuclease-deficient POLG in a large mammal, elevated somatic mtDNA mutations, systemic progeroid phenotypes including anaemia and hair/weight changes, apoptosis-driven tissue degeneration and shortened lifespan; the ROS-independence and stem-cell-exhaustion specifics are consistent extensions rather than contradictions.

Age-related loss of thermogenic adipocytes in subcutaneous white adipose tissue (scWAT) is caused by a progressive die-back of sympathetic nerve terminals, which itself is driven by the loss of adipocyte-derived neurotrophic support. As adipocytes age they downregulate secreted neurotrophic/neuritogenic factors (e.g. NRG4, BDNF, S100B), the local axonal arbor retracts, and the noradrenergic signal needed to recruit beige adipocytes never reaches the progenitor niche. Mechanism: Reduced adipocyte-to-axon trophic signalling → retraction/pruning of tyrosine-hydroxylase-positive terminals and reduced terminal density per adipocyte → lower local norepinephrine delivery → failure of β3-adrenergic→cAMP→PKA→p38→PGC-1α/UCP1 induction after cold or β3-agonist challenge. The adipocyte defect is upstream; the neuron is the proximate executor. Prediction: In aged mice, whole-mount TH imaging shows reduced sympathetic arbor density in scWAT that precedes the fall in UCP1+ adipocytes, and aged scWAT is refractory to cold but still responds normally to a cell-autonomous bypass of the nerve (direct β3-agonist, forskolin, or dibutyryl-cAMP ex vivo). Adipocyte-specific restoration of the neurotrophic factor in old mice re-grows the arbor and restores cold-induced beiging; adipocyte-specific deletion in young mice phenocopies the aged arbor and the beiging defect. Denervation-independent interventions should not rescue if nerve loss is the sole lesion — so the discriminating result is rescue by re-innervation without any change in adipocyte β3 receptor levels.

• GPT-5.6 Solmatch score 3compatible with the reference findingplausibility 4 of 5

  It correctly identifies reduced sympathetic innervation as a causal intermediate but assigns its origin to loss of adipocyte-derived trophic support, omitting microglial ALKBH5, Ntf5 and PVH TrkB-positive neurons. Adipose neurotrophic support and age-related axonal retraction are credible, so this could operate alongside the published pathway.

• Grok 4.7match score 3compatible with the reference findingplausibility 4 of 5

  Withdrawal of scWAT sympathetic innervation is the correct downstream effector that removes noradrenergic drive to beige adipocytes, but the upstream driver is assigned to adipocyte-derived NRG4, BDNF, and S100B rather than microglial ALKBH5 demethylation of Ntf5 mRNA and PVH TrkB activation. Local trophic loss could coexist with the microglial circuit, and age-dependent sympathetic pruning in scWAT is well supported and testable.

• Gemini 4 Argon (medium)match score 2compatible with the reference findingplausibility 5 of 5a suitable alternative mechanism

  P3 shares the core anatomical outcome of reduced sympathetic innervation in scWAT and impaired neurotrophic signalling (citing BDNF/TrkB ligand family members), but places the upstream defect in peripheral adipocytes rather than central hypothalamic microglia and ALKBH5/Ntf5. Both central microglial restraint of PVH neurons and reduced peripheral adipocyte trophic support can coexist and contribute additively to sympathetic arbor loss.

Maternal ageing elevates CD38 on decidual and circulating immune cells, depleting NAD+ in the shared placental microenvironment and thereby suppressing SIRT1/PARP activity in trophoblasts, which accelerates placental cellular senescence and metabolic failure. Restoring NAD+ or inhibiting maternal CD38 should reverse placental senescence and improve fetal growth. Mechanism: Maternal CD38-driven NAD+ depletion creates a metabolic niche that forces trophoblast senescence. Prediction: Placental NAD+ and SIRT1 activity fall with maternal age in parallel with CD38+ immune infiltration; CD38 inhibition or NAD+ precursors restore trophoblast NAD+/SIRT1, reduce senescence markers, and improve fetal outcomes even when maternal chronological age is unchanged.

• GPT-5.6 Solmatch score 3compatible with the reference findingplausibility 4 of 5

  It correctly identifies immune-cell CD38, NAD+ depletion, placental senescence, and rescue by CD38 inhibition or NAD+ replenishment. However, it omits inflammatory/SASP activation of IRF5 and assigns the critical NAD+ loss primarily to trophoblasts rather than decidual stromal cells.

• Claude Opus 5.5match score 4compatible with the reference findingplausibility 5 of 5

  Captures the central finding: immune-cell CD38 depleting NAD+ to drive placental senescence, rescued by CD38 inhibition or NAD+ precursors; it misses the IRF5 upstream step and names trophoblasts rather than decidual stromal cells as the NAD+-depleted target.

• Gemini 4 Argon (medium)match score 4compatible with the reference findingplausibility 5 of 5

  Correctly identifies the central causal mechanism of immune cell CD38 elevation depleting placental NAD+ to drive senescence, as well as rescue via CD38 inhibition or NAD+ precursors. It misses the upstream IRF5 activation and focuses on trophoblasts rather than decidual stromal cells as the primary NAD+-depleted target, warranting a 4 rather than 5.

The age-related failure of telogen-to-anagen transition is driven by loss of miR-205 in bulge hair follicle stem cells, and stem-cell-restricted restoration of miR-205 in already-aged follicles is sufficient to reactivate them and restore hair shaft regeneration. The defect corrected is mechanical rather than mitogenic: aged HFSCs are over-tensed and therefore unable to transduce dermal activating cues that are still present. Mechanism: miR-205 represses a coherent module of PI3K/AKT and actomyosin-contractility transcripts (PTEN-pathway components, actin nucleators, Rho-effector/myosin regulators) in CD34+ bulge cells. Reduced stress-fibre load and lower cortical and nuclear-envelope tension restore nuclear deformability, which relieves mechanically gated repression at cycle-entry loci and lowers the quiescence threshold. The follicle then crosses into anagen using the existing, unchanged dermal Wnt/FGF signal, so the rescued deficit is in signal responsiveness, not ligand supply. Because the intervention lowers a threshold rather than adding a mitogen, it should be effective only in follicles whose bulge is still intact. Prediction: In 18–24-month mice without depilation, HFSC-restricted miR-205 gain of function converts spontaneous telogen follicles to anagen within days, with a measurable fall in phospho-myosin-light-chain and in nuclear stiffness (AFM/micropipette) in sorted CD34+ cells that precedes Ki67 induction; an equally mitogenic stimulus that does not reduce cell tension fails in the same cohort. Conversely, miR-205 deletion in young HFSCs blocks anagen entry even under pharmacological Wnt activation. A ligand-deficit or niche model predicts the opposite ordering: rescue by added activator and no requirement for a tension change.

• GPT-5.6 Solmatch score 2compatible with the reference findingplausibility 4 of 5a suitable alternative mechanism

  Like P2, it addresses aged bulge stem-cell reactivation and anagen entry but substitutes miR-205 and reduced cellular tension for TPP1, telomere capping, and telomerase recruitment. Its temporal and biomechanical predictions make it a plausible competing or complementary mechanism.

• Grok 4.7match score 2compatible with the reference findingplausibility 4 of 5a suitable alternative mechanism

  Reactivation is assigned to stem-cell-restricted miR-205 restoration, reduced contractility, and a lower quiescence threshold in intact bulges, using endogenous Wnt/FGF. The causal chain is mechanical responsiveness rather than TPP1, shelterin function, or telomerase recruitment, yet both pathways can operate together. The tension-before-Ki67 order and the intact-bulge limit are credible, specific predictions grounded in known HFSC biology.

• Gemini 4 Argon (medium)match score 2compatible with the reference findingplausibility 5 of 5a suitable alternative mechanism

  Like P2, this hypothesis centres on bulge HFSC reactivation and telogen-to-anagen transition via miR-205-mediated mechanical softening rather than TPP1 and telomerase recruitment. It represents a different causal regulator within the same cell type and physiological transition, is compatible as an independent pathway, and is well grounded in published HFSC biology.

Obesity changes the cargo of adipocyte-derived extracellular vesicles, and these vesicles — not soluble factors — are the vehicle that carries the pathogenic signal to the joint, delivering microRNAs that silence cartilage anabolic programs. Mechanism: Hypertrophic and hypoxic adipocytes export EVs enriched in specific miRNAs (e.g. miR-34a/miR-146a family members) and in lipolysis-derived lipids; these are taken up by chondrocytes and synoviocytes, repress SOX9/TIMP and PPARγ targets, and de-repress NF-κB-dependent proteases. Prediction: Intra-articular injection of EVs purified from obese (but not lean) adipose tissue induces cartilage degradation in lean mice; adipocyte-specific blockade of EV biogenesis (Rab27a or nSMase2 deletion) protects obese mice, and deleting the implicated miRNA from adipose tissue abolishes transfer of the phenotype even though adiposity and circulating leptin remain elevated.

• GPT-5.6 Solmatch score 3compatible with the reference findingplausibility 4 of 5

  It correctly identifies adipocyte-derived extracellular vesicles as a pathogenic vehicle reaching chondrocytes, but assigns causality to microRNAs and lipids instead of mitochondrial DNA–cGAS–STING signaling. Adipose EV microRNA effects are plausible and directly testable.

• Grok 4.7match score 3compatible with the reference findingplausibility 4 of 5

  This identifies adipocyte-derived extracellular vesicles as the vehicle that carries a pathogenic signal into chondrocytes and predicts that blocking adipocyte EV biogenesis protects joints. It substitutes miRNA cargo and anabolic/NF-κB repression for mitochondrial DNA and cGAS-STING; both cargoes can travel in the same vesicles, and an adipose EV–miRNA mechanism remains a plausible, testable account.

• Gemini 4 Argon (medium)match score 3compatible with the reference findingplausibility 5 of 5

  Correctly identifies adipocyte-derived extracellular vesicles taken up by chondrocytes as the causal vehicle linking obesity to cartilage degeneration, but attributes the pathogenic cargo and downstream pathway to microRNAs and SOX9/NF-κB rather than mitochondrial DNA, cGAS-STING, and senescence. Adipocyte EV miRNA transfer is highly plausible and compatible alongside mtDNA transfer.

Age-associated mitochondrial dysfunction originates in long-lived, dictyate-arrested oocytes, where the acute bioenergetic surge of follicular recruitment triggers VDAC1/3 oligomerization and cytosolic efflux of oxidized mtDNA to activate oocyte cGAS. Rather than inducing immediate germ cell death, oocyte-synthesized 2'3'-cGAMP traverses transzonal projections (TZPs) via Connexin 37 and Connexin 43 gap junctions into coupled granulosa cells, where it activates STING1 to drive paracrine sterile inflammation, bidirectional metabolic uncoupling, and follicular atresia. Mechanism: During prolonged prophase I dictyate arrest, declining TFAM packaging and PINK1-Parkin mitophagy allow point mutations, cristae disorganization, and mitochondrial reactive oxygen species (mROS) to accumulate silently in the oocyte. When cohorts of follicles are recruited into the gonadotropin-dependent growth phase, the mandatory >100-fold amplification in oxidative phosphorylation acutely overloads defective electron transport chains, inducing voltage-dependent anion channel (VDAC1/3) oligomerization and extruding oxidized mtDNA (ox-mtDNA) fragments into the oocyte cytosol. Because oocytes transcriptionally repress STING1 and gasdermin-mediated death pathways to safeguard germline survival, cytosolic ox-mtDNA binding to cyclic GMP-AMP synthase (cGAS) converts the oocyte into a non-lytic generator of the second messenger 2'3'-cGAMP. Oocyte-derived 2'3'-cGAMP is exported across TZPs through heterotypic/homotypic Connexin 37 (GJA4) gap junctions at the oocyte-cumulus interface and propagates laterally across cumulus and mural granulosa syncytia via Connexin 43 (GJA1). In metabolically coupled granulosa cells, imported 2'3'-cGAMP activates ER-resident STING1-TBK1-IRF3/NF-kappaB signaling, inducing type I interferons (IFN-beta), IL-6, TNF-alpha, and CXCL10. This somatic inflammatory program triggers actin-myosin-mediated TZP retraction, suppresses FSH-stimulated aromatase (CYP19A1) estradiol synthesis, and severs the gap-junctional supply of pyruvate, NAD+ precursors, and meiotic-arresting cGMP back to the oocyte, culminating in premature meiotic resumption, spindle instability, and antral follicular atresia. Prediction: In naturally aged mice and heterochronic chimeric reaggregated follicles (combining aged oocytes with young somatic cells), oocyte-specific deletion of Cgas (Zp3-Cre or Gdf9-Cre;Cgas^fl/fl) paired with wild-type granulosa cells—or granulosa-specific deletion of Sting1 (Cyp19a1-Cre or Amhr2-Cre;Sting1^fl/fl) paired with aged wild-type oocytes—will abolish perifollicular TBK1/IRF3 phosphorylation, preserve TZP density and estradiol output, and restore oocyte developmental competence; conversely, granulosa-specific Cgas deletion (Cyp19a1-Cre;Cgas^fl/fl) will fail to prevent granulosa STING1 activation and follicular demise when coupled via intact Cx37 gap junctions to aged Cgas-wild-type oocytes.

• GPT-5.6 Solmatch score 5compatible with the reference findingplausibility 5 of 5

  It states the full causal finding: mitochondrial DNA escapes from ageing oocytes, activates oocyte cGAS, and produces cGAMP that crosses gap junctions to activate granulosa-cell STING, causing inflammation and ovarian dysfunction. Its genetic and pharmacological logic closely matches the causal rescue evidence, although some detailed upstream and downstream embellishments remain to be tested.

• Grok 4.7match score 5compatible with the reference findingplausibility 5 of 5

  The hypothesis states the published sequence: oocyte mtDNA leak activates oocyte cGAS, 2'3'-cGAMP crosses Cx37/Cx43 gap junctions, and granulosa STING drives inflammation, metabolic uncoupling, and atresia, with oocyte Cgas or granulosa Sting1 deletion rescuing competence. The steps align with established cGAMP permeation of gap junctions and oocyte–granulosa coupling and are directly testable.

• Claude Opus 5.5match score 5compatible with the reference findingplausibility 5 of 5

  States the published axis precisely: oocyte mtDNA leakage activating oocyte cGAS, non-lytic cGAMP transfer through connexin gap junctions to granulosa STING, driving inflammation and follicular decline, with the matching cell-type-specific genetic tests.

SIRT1 directly silences full-length, transposition-competent L1 retrotransposons by deacetylating H4K16ac and H3K9ac at the L1 5' UTR and deacetylating SUV39H1 at Lys266 to maintain repressive H3K9me3 heterochromatin. Age- or stress-associated loss of this SIRT1–SUV39H1 axis derepresses L1 transcription and drives cytoplasmic L1 cDNA accumulation, which activates the cGAS–STING–TBK1–IRF3 pathway to induce Type I interferon signaling and sustain the senescence-associated secretory phenotype (SASP) independently of canonical NF-κB/RelA deacetylation. Mechanism: In proliferating somatic cells, nuclear SIRT1 occupies the 5' UTR CpG-rich promoter of intact L1HS and L1PA elements, where its NAD+-dependent deacetylase activity removes euchromatic H4K16ac and H3K9ac marks while deacetylating the histone methyltransferase SUV39H1 at K266. Deacetylated SUV39H1 exhibits heightened catalytic activity, depositing dense H3K9me3 that stabilizes KAP1 (TRIM28) and HP1α co-repressor complexes to block RNA Polymerase II initiation. When SIRT1 levels or nuclear NAD+ decline during ageing, H4K16ac and H3K9ac accumulate while SUV39H1 K266 acetylation rises, eroding H3K9me3 at L1 promoters and licensing transcription of full-length L1 mRNAs. Exported L1 transcripts assemble into ribonucleoproteins with ORF1p and ORF2p and undergo target-primed or cytoplasmic reverse transcription into extrachromosomal L1 ssDNA/cDNA and RNA–DNA hybrids. Cytoplasmic L1 cDNA binds and activates cGAS, generating 2'3'-cGAMP to trigger STING–TBK1–IRF3/NF-κB signaling, which drives late-stage Type I interferon (IFN-β, ISG15, OAS1) expression and reinforces inflammatory SASP cytokine secretion even when direct SIRT1-mediated deacetylation of RelA/p65 (K310) is already lost. Prediction: Unlike hypotheses attributing SIRT1-deficient SASP solely to direct RelA-K310 hyperacetylation or pioneer factor recruitment, CRISPR/shRNA depletion of SIRT1 or expression of catalytically dead SIRT1-H363Y in primary human fibroblasts will specifically increase H4K16ac/H3K9ac and reduce SUV39H1 occupancy and H3K9me3 at L1HS 5' UTRs (by CUT&Tag), followed by ORF1p accumulation and cytoplasmic L1 cDNA enrichment prior to peak IFN-I induction; critically, expression of a constitutively active, deacetylation-mimetic SUV39H1-K266R mutant stops L1 transcription, and pharmacological blockade of L1 reverse transcription with lamivudine (3TC) or cGAS inhibition (RU.521) will abolish cytoplasmic L1 cDNA and rescue the IFN-I/SASP signature despite persistent RelA-K310 hyperacetylation.

• GPT-5.6 Solmatch score 4compatible with the reference findingplausibility 4 of 5

  It reproduces the central causal chain, including L1 repression, KAP1-associated H3K9me3, cGAS–STING activation after SIRT1 loss, senescence-associated inflammation, and 3TC rescue. It omits the crucial Lamin B1–KAP1 recruitment mechanism and substitutes direct histone and SUV39H1 deacetylation, but this credible chromatin pathway could act in parallel.

• Grok 4.7match score 3compatible with the reference findingplausibility 4 of 5

  It recovers SIRT1-dependent H3K9me3/KAP1 repression of L1 transcription, cGAS–STING/IFN–SASP, and 3TC rescue, while substituting SUV39H1-K266 and H4K16/H3K9 deacetylation for Lamin B1–KAP1 recruitment. Those deacetylase activities and the L1–cGAS pathway are credible and can coexist with a Lamin B1 role.

• Claude Opus 5.5match score 4compatible with the reference findingplausibility 4 of 5

  Captures the central finding — SIRT1 silences L1 at the 5'-UTR via KAP1-associated repressive H3K9me3 heterochromatin, and loss derepresses L1 to drive cGAS-STING/SASP with 3TC rescue — but attributes H3K9me3 maintenance to SUV39H1 deacetylation rather than Lamin B1, and omits Lamin B1 entirely; the proposed SIRT1–SUV39H1 axis is well grounded in published biology.

Age at in vivo mutation correction is a causal moderator of multilevel skeletal rescue: early postnatal correction yields quantitatively greater recovery across molecular, cellular, and structural/mechanical bone endpoints than later postnatal or adult correction under matched delivery and bone-lineage editing efficiency. Mechanism: Earlier allelic correction intercepts progerin-driven nuclear disruption, DNA damage, and senescence before cumulative architectural loss locks in; remaining growth-related accrual and remodeling capacity then amplify the phenotypic return from the same molecular fix, producing larger effect sizes at every hierarchical level. Prediction: In a factorial design (early vs late × corrected vs sham) with bone editing efficiency matched or covaried, the timing × correction interaction will significantly exceed the main effect of correction alone on bone progerin clearance, osteoblast surface/mineral apposition rate, micro-CT architecture, and ultimate load, with early correction showing larger standardized effect sizes at each level.

• GPT-5.6 Solmatch score 4compatible with the reference findingplausibility 4 of 5

  Captures correction-driven multilevel skeletal rescue and the greater benefit of early treatment across molecular, cellular, structural, and mechanical endpoints. However, it reframes age as an independent moderator under matched editing efficiency, whereas the published finding also attributes early efficacy to substantially greater editing, and it does not explicitly emphasize matrix deposition and mineralization.

• Claude Opus 5.5match score 5compatible with the reference findingplausibility 5 of 5

  States the full causal finding: in vivo correction rescues molecular, cellular and structural/mechanical bone endpoints, with age at treatment as the moderator favouring early postnatal delivery.

• Gemini 4 Argon (medium)match score 4contradicts the reference findingplausibility 5 of 5

  P4 captures all major phenotypic endpoints—LMNA correction, progerin reduction, osteoblast matrix/mineralization rescue, structural/mechanical rescue, and strong age-dependence across all levels—though it frames the age effect as holding under matched editing efficiency whereas the published study found early delivery produced substantially greater editing itself.

A specific DHT-inducible secreted or intracellular amplifier protein (e.g. a stress-response factor such as RBP4/SFRP2/DKK1-class or a cytokine like IL-6/TGF-β1) acts as the obligate intermediate that exacerbates DHT's mitochondrial and senescence effects; DHT alone is weakly damaging, and the amplifier is required for the full phenotype. Mechanism: AR activation raises transcription of the amplifier; the secreted factor acts autocrine/paracrine on dermal papilla and outer root sheath cells, suppressing Wnt/β-catenin and PGC-1α-driven mitochondrial biogenesis while activating NF-κB, which raises NOX4 and inflammatory ROS. The resulting bioenergetic deficit plus redox stress drives p53–p21 senescence and premature catagen. Prediction: Neutralizing antibody or knockdown of the amplifier in DHT-treated cells restores OCR, PGC-1α and hair-shaft elongation in ex vivo follicle culture, while adding recombinant amplifier alone (no DHT) reproduces mitochondrial dysfunction and senescence; amplifier levels are elevated in balding versus occipital scalp dermal papilla.

• GPT-5.6 Solmatch score 2compatible with the reference findingplausibility 3 of 5

  It recognizes a DHT-inducible amplifier and explicitly lists SFRP2 as a candidate, but neither identifies FSTL1 as its binding partner nor proposes stabilization of FSTL1 or the demonstrated knockdown epistasis. An autocrine amplifier involving Wnt, NF-κB and NOX4 is possible but remains nonspecific and speculative.

• Grok 4.7match score 3compatible with the reference findingplausibility 4 of 5

  A DHT-induced secreted amplifier of the SFRP2/DKK1 class is cast as required for the mitochondrial and senescence phenotype, with knockdown rescue, which hits the right functional class while omitting FSTL1 binding and SFRP2-dependent protein stabilization in favor of Wnt, PGC-1α and NF-κB signaling that can still coexist with that axis. Androgen-induced dermal-papilla secreted factors are established mediators of follicular regression, and the antibody, knockdown and recombinant-protein tests are specific.

• Gemini 4 Argon (medium)match score 2compatible with the reference findingplausibility 4 of 5a suitable alternative mechanism

  Proposes the right class of mechanism (a DHT-inducible secreted amplifier protein in dermal papilla cells, even listing SFRP2 among several candidate examples), but hedges across multiple candidates and misses the specific FSTL1 binding and protein-stabilization axis. It is compatible with the ground truth and represents a highly credible model of paracrine/autocrine amplification in androgenetic alopecia.

In ulcerative colitis, metabolic stress in mucosal T cells causes mitochondrial DNA to leak into the cytosol, activating the cGAS–STING pathway and driving these cells into a senescent, SASP-secreting state that worsens colitis. Blocking mtDNA release or STING signaling should prevent senescence and attenuate disease. Mechanism: Inflamed mucosal metabolic conditions damage mitochondria in lamina propria T cells; mitochondrial permeability transition/VDAC- or BAX/BAK-dependent pore formation releases mtDNA into the cytosol; cGAS detects it, STING–TBK1–IRF3/NF-κB signaling plus p53/p21 engagement enforces a stable cell-cycle arrest with a pro-inflammatory secretome (IL-6, IL-1β, TNF, chemokines) that recruits and activates neutrophils and macrophages, sustaining epithelial injury. Prediction: In colitis models, T-cell-specific deletion of Cgas or Sting1 (or mtDNA depletion/TFAM-dependent packaging rescue, or inhibition of the mPTP/VDAC oligomerization) reduces p16/p21-positive senescent mucosal T cells and SASP cytokines and lessens histological colitis, whereas deleting the same genes in epithelium or myeloid cells does not reproduce the senescence rescue; cytosolic mtDNA is measurable in sorted UC patient mucosal T cells and correlates with their senescence score.

• GPT-5.6 Solmatch score 4compatible with the reference findingplausibility 5 of 5

  It closely reproduces the central causal chain from mitochondrial dysfunction and cytosolic mitochondrial DNA through cGAS-STING-dependent T-cell senescence to worsened colitis. It leaves NAD+ dysregulation unspecified, does not restrict the cells to CD8+ T cells, and does not directly test senolytic clearance, but is otherwise a strong, specific, and testable explanation.

• Grok 4.7match score 4compatible with the reference findingplausibility 5 of 5

  Metabolic injury of mucosal T cells, cytosolic mtDNA release, cGAS–STING activation, and a SASP-secreting senescent state that worsens colitis restate the central causal sequence and match established mtDNA sensing. NAD+ is generalized to metabolic stress, CD8+ cells are broadened to T cells, and senolytic clearance is unstated, so one specific initiator remains vaguer while the hypothesis stays fully compatible and directly testable.

• Gemini 4 Argon (medium)match score 4compatible with the reference findingplausibility 5 of 5

  P5 accurately states the central causal pathway—metabolic stress in mucosal T cells causing cytosolic mtDNA leakage and cGAS-STING activation to drive pathogenic T-cell senescence that exacerbates colitis—while being slightly vaguer on the specific NAD+ defect, CD8+ subset, and systemic senolytic clearance. It is a well-supported, specific, and directly testable mechanism.

Naturally occurring maternal mtDNA haplotype variation causally accelerates ovarian ageing when nuclear genomes are held equivalently heterogeneous across comparison groups (reciprocal F1/F2 or conplastic designs). Females inheriting a high-ROS mtDNA haplotype deplete primordial follicles faster, develop earlier stromal fibrosis and vascular decline, lose cyclicity sooner, and show steeper AMH decline and FSH rise at matched chronological ages than females carrying a low-ROS haplotype on the same nuclear-background distribution. Mechanism: mtDNA haplotype–dependent impairment of mitochondrial quality control in oocytes and granulosa cells elevates ROS, increases apoptosis-driven follicle atresia, and secondarily drives inflammatory stromal remodelling and microvascular rarefaction. Prediction: In age-matched cohorts with equivalently heterogeneous nuclear genomes, the high-ROS mtDNA group shows steeper age slopes for follicle loss, atresia fraction, ovarian histopathology scores, endocrine decline, and fertility span; swapping only mtDNA (conplastic or nuclear-transfer controls) reverses the phenotype, whereas matching mtDNA abolishes the difference—falsifying pure nuclear or developmental-set-point explanations.

• GPT-5.6 Solmatch score 4compatible with the reference findingplausibility 4 of 5

  It states the central causal finding that mtDNA haplotype alters ovarian-ageing rate on equivalently heterogeneous nuclear backgrounds and predicts the main tissue, mitochondrial and functional phenotypes. It misses the specific TOMM20–TFAM import and mtDNA-maintenance mechanism, substituting a high-ROS quality-control mechanism that could operate concurrently.

• Claude Opus 5.5match score 4compatible with the reference findingplausibility 5 of 5

  Captures the central causal finding — maternal mtDNA haplotype accelerates follicle depletion, fibro-inflammatory remodelling and functional decline with nuclear backgrounds held equivalent — but attributes it to high-ROS failure of mitochondrial quality control rather than reduced TOMM20/mitochondrial TFAM and impaired mtDNA maintenance, so the specific molecular mechanism is missed.

• Gemini 4 Argon (medium)match score 3compatible with the reference findingplausibility 5 of 5

  Correctly identifies that maternal mtDNA haplotype variation causally accelerates primordial follicle loss, stromal fibrosis, and ovarian functional decline on equivalent heterogeneous nuclear backgrounds, but attributes the cellular mechanism to general mitochondrial quality control and ROS rather than defective TOMM20-mediated TFAM import and mtDNA maintenance.

Mesenchymal stromal cell–derived extracellular vesicles (MSC-EVs) alleviate UV-induced skin photoaging by restoring PINK1–Parkin-dependent mitophagy in keratinocytes and dermal fibroblasts. Clearance of damaged mitochondria reduces cytosolic mitochondrial DNA, suppressing cGAS–STING signaling and the inflammatory reinforcement of cellular senescence. Mechanism: MSC-EVs increase mitochondrial delivery to lysosomes, reducing mitochondrial DNA leakage and downstream STING–TBK1–IRF3 signaling. Prediction: Protection is lost after PINK1 or PRKN disruption despite equivalent EV uptake; cGAS deletion rescues the inflammatory phenotype downstream of defective mitophagy. Increased mitophagic flux precedes reduced cytosolic mitochondrial DNA, senescence, and collagen degradation.

• Grok 4.7match score 4compatible with the reference findingplausibility 5 of 5

  It states the central chain: enhanced mitophagy clears damaged mitochondria, lowers cytosolic mtDNA, and suppresses cGAS–STING inflammation and senescence, with mitophagy loss abolishing protection. The vehicle is narrowed to EVs and PINK1–Parkin, and the rescue is placed at cGAS deletion rather than STING inhibition.

• Claude Opus 5.5match score 5compatible with the reference findingplausibility 5 of 5

  Matches the published mechanism fully: MSC-derived cell-free secretome/EVs enhance mitophagy, clearing damaged mitochondria, lowering cytosolic mtDNA and cGAS-STING-driven inflammation and senescence, with mitophagy loss abolishing and downstream cGAS/STING blockade restoring protection. Specifying PINK1-Parkin is a reasonable refinement rather than a conflict.

• Gemini 4 Argon (medium)match score 5compatible with the reference findingplausibility 5 of 5

  P1 accurately captures the entire causal chain of the published finding, including MSC cell-free therapy enhancing mitophagy, clearing damaged mitochondria to reduce cytosolic mtDNA leakage, suppressing cGAS-STING signaling, and the epistatic effects of inhibiting mitophagy versus cGAS-STING.

Age-related upregulation of the transmembrane protein causally drives cellular senescence and tissue degeneration by constitutively activating the PI3K-AKT-mTORC1 signaling axis and suppressing autophagic clearance of damaged organelles. Genetic ablation or neutralizing blockade of this protein attenuates senescence marker accumulation (p16INK4a, p21CIP1, SA-β-gal) and ameliorates age-associated tissue fibrosis and dysfunction. Mechanism: Ligand engagement or clustering of the transmembrane protein recruits PI3K to its intracellular domain, elevating PIP3 levels to phosphorylate AKT and activate mTORC1, which in turn phosphorylates and inhibits ULK1 and TFEB, halting autophagic-lysosomal flux, increasing damaged mitochondrial accumulation, and stabilizing p53/p21CIP1 and p16INK4a expression. Prediction: Depletion of the transmembrane protein will reduce S6K1/4E-BP1 phosphorylation and restore autophagic flux (LC3-II turnover), whereas pharmacological inhibition of autophagy (e.g., bafilomycin A1) or constitutive mTORC1 activation will completely abolish the anti-senescent rescue effect of depleting the protein without initially altering upstream DNA damage sensors.

• GPT-5.6 Solmatch score 4compatible with the reference findingplausibility 4 of 5

  It correctly identifies protein upregulation as pro-senescent, genetic loss as protective, and AKT activation as the central signaling event, while also predicting reduced fibrosis and dysfunction. It misses the specific median-lifespan and lung-function results and adds an unestablished PI3K–mTORC1–autophagy mechanism downstream of AKT, but that extension is biologically credible and testable.

• Grok 4.7match score 4compatible with the reference findingplausibility 4 of 5

  The hypothesis states that age-related upregulation drives senescence through PI3K–AKT–mTORC1 and that depletion lowers p16/p21/SA-β-gal and eases tissue fibrosis and dysfunction, while median lifespan and lung-function preservation stay unspecified and autophagy is an added downstream step. This AKT-centered account can hold together with AKT rescue of the phenotype, and PI3K–AKT–mTOR control of senescence is a specific, well-supported mechanism.

• Claude Opus 5.5match score 5compatible with the reference findingplausibility 5 of 5

  Captures the core finding: age-related upregulation of the transmembrane protein drives senescence and tissue fibrosis via PI3K-AKT(-mTORC1), with ablation reducing senescence markers and the rescue abolished by restoring downstream signaling; the added autophagy/mTORC1 detail is a plausible extension rather than a conflict.

A microprotein translated from a small ORF within a lncRNA or 5' uORF is depleted in Alzheimer's disease neurons, and this loss causally impairs mitochondrial respiration independently of any annotated protein at the same locus. Mechanism: The microprotein localizes to the inner mitochondrial membrane and stabilizes assembly of respiratory complex I/IV or ATP synthase dimers. Depletion lowers ATP output and raises mitochondrial ROS, which degrades synaptic maintenance in high-demand neurons. Prediction: CRISPR knockout of only the sORF start codon (leaving the host transcript and any overlapping annotated ORF intact) reduces oxygen consumption rate and complex activity in neurons, and re-expression of the microprotein cDNA from a separate locus rescues it; knockdown of the host lncRNA by itself does not reproduce the defect.

• GPT-5.6 Solmatch score 3compatible with the reference findingplausibility 4 of 5

  It correctly links loss of a disease-depleted microprotein to impaired mitochondrial respiration, but places the effect in neurons and does not identify the 63-amino-acid MKKS product or its predominant translation. Respiratory-complex regulation by mitochondrial microproteins is biologically credible and the proposed selective knockout and rescue tests are strong.

• Grok 4.7match score 3compatible with the reference findingplausibility 5 of 5

  Correctly identifies loss of a small-ORF product, independent of the annotated protein at the same locus, as impairing mitochondrial respiration, but assigns this to neurons and a lncRNA or uORF rather than the 63-aa MKKS product in microglia. Mitochondrial microproteins are an established class, and the start-codon knockout plus cDNA rescue is a strong, specific test.

• Gemini 4 Argon (medium)match score 3compatible with the reference findingplausibility 5 of 5

  Correctly identifies the core mechanism—an AD-downregulated microprotein from a 5' uORF whose loss causally impairs mitochondrial respiration independently of the locus's annotated protein—but attributes the effect to neurons rather than microglia and lacks the specific MKKS locus identity. Enrichment of sORF microproteins in the inner mitochondrial membrane makes this highly plausible.

Natural variation in seed longevity among rice varieties is caused mainly by cis-regulatory polymorphisms in a seed-expressed lipoxygenase gene (OsLOX3/LOX2 family) under a major longevity QTL. Long-lived alleles reduce LOX expression in the embryo and aleurone, which slows lipid peroxidation during storage. Mechanism: LOX oxidizes polyunsaturated fatty acids in stored lipids and membranes into hydroperoxides and reactive aldehydes such as hexanal and MDA. These damage membranes, proteins and DNA, so the embryo gradually loses viability. Promoter or enhancer haplotypes that lower LOX transcription, or loss-of-function variants, reduce this oxidative damage. Prediction: Varieties with the long-lived haplotype show lower embryo LOX transcript levels and activity, and less hexanal and MDA after accelerated or natural ageing. Near-isogenic lines, promoter swaps and CRISPR knockout of LOX in a short-lived background should recover most of the QTL effect, with no penalty in yield, grain quality or dormancy. Changing other antioxidant genes in the interval should not reproduce the effect.

• GPT-5.6 Solmatch score 2contradicts the reference findingplausibility 5 of 5

  Reduced lipoxygenase activity is a strong, specific and testable explanation for slower lipid peroxidation, but it substitutes a LOX cis-regulatory variant for the demonstrated causal qSL6 thioesterase allele. Its claim that LOX explains most of the major QTL effect conflicts with the published causal assignment to SL6.

• Grok 4.7match score 3contradicts the reference findingplausibility 5 of 5

  The hypothesis correctly centers natural cis-regulatory control of embryo and aleurone lipid peroxidation, with a storability gain that spares agronomic performance, but the causal gene is the fatty acyl-ACP thioesterase SL6, which remodels palmitic-acid content, is activated by ABA–VP1, and is stabilized by a virus-derived CT-rich 5′ UTR. Making LOX the main cause of varietal differences conflicts with qSL6/SL6 accounting for that variation; LOX itself remains a specific, well-supported rice storability candidate.

• Gemini 4 Argon (medium)match score 2compatible with the reference findingplausibility 5 of 5a suitable alternative mechanism

  Addresses cis-regulatory variation affecting lipid peroxidation and fatty acid oxidation in seeds, closely aligning with the physiological mechanism class of the finding, but identifies lipoxygenase (LOX) rather than the fatty acyl-ACP thioesterase SL6 as the causal gene. It is compatible as another major QTL mechanism and strongly supported by known roles of LOX genes in rice seed storability.

Endothelial NAD+ collapse is the single convergent node through which vascular aging drives systemic senescence and shortens lifespan. Age-related CD38 induction and NAMPT decline in endothelium starve SIRT1 of NAD+, which simultaneously disables VEGF/Notch-dependent capillary maintenance (supply arm) and de-represses SERPINE1/PAI-1 and p21 (secretory arm), so one metabolite deficit produces both rarefaction and a blood-facing pro-geronic secretome. Mechanism: Perivascular inflammatory tone and senescent-cell CD38 expression raise NAD+ consumption while NAMPT transcription falls with loss of mechanotransduced KLF2 signalling at reduced/disturbed shear. Endothelial NAD+ drops below the Km of SIRT1. Consequences split along two limbs: (i) hyperacetylated Notch1 ICD and FOXO1 blunt myo-endothelial VEGF/Notch crosstalk, so sprouting and capillary density fail and intercapillary distance grows; (ii) hyperacetylated p53, FOXO1 and NF-kB/SMAD cofactors keep SERPINE1 and CDKN1A promoters active, so PAI-1 rises — stabilizing endothelial senescence cell-autonomously via the PAI-1/p53/IGFBP3 loop and circulating as a pro-geronic factor that induces senescence in distant parenchyma. Both limbs feed back: rarefaction lowers shear and local pO2, further suppressing KLF2/NAMPT. Prediction: Endothelium-restricted Nampt overexpression (or Cd38 deletion) initiated in 18-month-old mice restores capillary density, lowers plasma PAI-1 and multi-organ p16, and extends median lifespan. The discriminating result is the epistasis pattern: the lifespan benefit is largely abolished by concurrent endothelial Sirt1 deletion, and is substantially — but only partially — reproduced by endothelial Serpine1 deletion alone, which lowers plasma PAI-1 and parenchymal p16 while leaving capillary density only modestly improved. No competing framing (pure supply, pure clearance, pure transport-gating) predicts that one endothelial metabolic gene both rescues rarefaction and normalizes a circulating senescence mediator, with the rescue running through a single deacetylase.

• GPT-5.6 Solmatch score 3compatible with the reference findingplausibility 4 of 5

  It captures endothelial NAMPT/NAD+ collapse and the resulting vascular dysfunction, systemic senescence, and lifespan reduction, but specifies altered CD38 consumption and NAMPT transcription instead of C/EBPβ-induced AEP cleavage and omits the decisive AEP and NAMPT-N136A rescues. Its integrated metabolic model is plausible and testable, although the detailed SIRT1–Notch–PAI-1 chain is less firmly supported than the central NAD+ mechanism.

• Grok 4.7match score 3compatible with the reference findingplausibility 4 of 5

  This proposal identifies endothelial NAD+ collapse, involving NAMPT and acting through SIRT1, as the cause of capillary loss, PAI-1-linked senescence, and reduced lifespan, with CD38 and lower NAMPT transcription as the drivers. Extra NAD+ consumption and reduced NAMPT expression can coexist with proteolytic inactivation of NAMPT, and the Sirt1 versus Serpine1 epistasis prediction is a specific, plausible test.

• Gemini 4 Argon (medium)match score 3compatible with the reference findingplausibility 5 of 5

  Accurately pinpoints endothelial NAMPT decline and NAD+ collapse as the core node driving systemic senescence and shortened lifespan, while missing the specific C/EBPβ-induced AEP cleavage mechanism (proposing KLF2-mediated transcriptional decline and CD38 upregulation instead). It is a very strong, well-supported, and testable scientific hypothesis.

During single-positive thymocyte licensing, NRF1 and YY1 recruit the chromatin remodelers SRCAP and HIRA to deposit labile double-variant H2A.Z/H3.3 nucleosomes at the transcription start sites of oxidative phosphorylation, one-carbon, and ribogenesis genes, maintaining a permissive nucleosome-depleted region occupied by promoter-proximal paused RNA Polymerase II in resting naive T cells. Upon TCR costimulation, TIP60-mediated H2A.Z acetylation and P-TEFb recruitment trigger immediate Pol II pause-release and synchronous metabolic transcription. During ageing, slow homeostatic cell divisions combine with CD38-driven NAD+ depletion and SIRT1 loss to destabilize TIP60/SRCAP and unleash ANP32E-mediated H2A.Z eviction, replacing labile variant nucleosomes with canonical H2A/H3.1 nucleosomes that occlude the transcription start site and abolish Pol II poising. Mechanism: During late thymocyte maturation, a transient developmental wave of NRF1, YY1, and ATP-dependent chromatin remodeling directs the SRCAP complex and the histone chaperone HIRA to incorporate replication-independent H2A.Z and H3.3 histone variants into the -1 and +1 nucleosomes flanking the transcription start sites (TSSs) of mitochondrial respiratory chain subunits, one-carbon enzymes (Shmt2, Mthfd2), and ribosome biogenesis factors. Because double-variant H2A.Z/H3.3 nucleosomes are thermodynamically unstable, they prevent canonical nucleosome encroachment over the TSS in quiescent peripheral naive T cells, permitting constitutive pre-initiation complex assembly and loading of Ser5-phosphorylated RNA Polymerase II arrested 30–50 bp downstream by NELF and DSIF. This configuration decouples chromatin accessibility from basal bioenergetic execution, keeping metabolic mRNA output near zero at rest. Upon TCR/CD28 stimulation, calcineurin/NFAT and PI3K–AKT signaling activate the acetyltransferase TIP60 (KAT5) to acetylate H2A.Z (H2A.ZK4/K7ac), which recruits BRD4 and P-TEFb (CDK9) to phosphorylate NELF, DSIF, and Pol II CTD-Ser2 for immediate burst elongation. In aged organisms, thymic involution forces naive T cells to undergo replication-coupled canonical H2A/H3.1 incorporation during homeostatic division, while systemic inflammageing upregulates ecto-enzymatic CD38, depleting intracellular NAD+ in T cells. Loss of NAD+ inactivates SIRT1, which normally deacetylates and stabilizes SRCAP and TIP60 against ubiquitin-proteasomal degradation, shifting the nuclear balance toward the histone chaperone ANP32E. ANP32E actively evicts residual unacetylated H2A.Z from metabolic TSSs, allowing stable canonical H2A/H3.1 nucleosomes to slide across the promoter and block Pol II pre-loading, while TATA-box-containing inflammatory genes that do not rely on H2A.Z-dependent paused Pol II remain inducible. Prediction: CUT&Tag for H2A.Z, H3.3, canonical H3.1, and Ser5-P/Ser2-P Pol II coupled with PRO-seq in resting young versus aged naive T cells will reveal a selective pre-activation loss of -1/+1 H2A.Z/H3.3 double-variant nucleosomes, encroachment of canonical H3.1 over the TSS, and disappearance of promoter-proximal paused Pol II at NRF1/YY1-regulated OXPHOS and ribogenesis loci despite preserved 3D enhancer loops and unmethylated DNA. Supporting this mechanism over bivalent-histone or 3D-looping alternatives, inducible peripheral deletion of Srcap or H2afz in young mature naive T cells will erase paused Pol II and selectively abrogate ultra-early (30–90 minute) nascent metabolic transcription upon anti-CD3/CD28 stimulation without altering steady-state resting mRNA levels, whereas genetic ablation of Anp32e or NAD+ repletion (via NMN/CD38 inhibition) during homeostatic maintenance in aged mice will preserve H2A.Z/Pol II poising and restore rapid bioenergetic activation.

• GPT-5.6 Solmatch score 3compatible with the reference findingplausibility 3 of 5

  It correctly identifies promoter H2A.Z loss as an age-sensitive defect affecting rapid metabolic activation, including OXPHOS genes, but replaces tonic IL-7 and GABPα with NRF1/YY1, SRCAP/HIRA, Pol II pausing, and NAD-dependent regulation. Several components are biologically possible, although the proposed SIRT1–SRCAP/TIP60 stabilization and ageing chain are speculative.

• Grok 4.7match score 3compatible with the reference findingplausibility 4 of 5

  It identifies the core lesion—H2A.Z at OXPHOS promoters in quiescent naive T cells, lost with age and required for rapid activation—while assigning deposition to NRF1/YY1–SRCAP/HIRA and loss to CD38–NAD–SIRT1–ANP32E instead of tonic IL-7 and GABPα. Those routes can coexist with an IL-7–GABPα program; SRCAP, HIRA, ANP32E, TIP60, and paused Pol II are established, although SIRT1 stabilization of SRCAP is not.

• Claude Opus 5.5match score 4compatible with the reference findingplausibility 5 of 5

  Captures the central finding—developmentally established H2A.Z deposition at OXPHOS/anabolic gene TSSs priming rapid metabolic activation, lost with age and rescuable by preventing H2A.Z loss—with the main divergence being the upstream trigger (NRF1/YY1/SRCAP and NAD+/ANP32E rather than tonic IL-7 signaling via GABPα). Strong, specific and mechanistically well-grounded in chromatin biology.

The involuting perimenopausal ovary is the seed organ of female brain ageing: its p16/p21-positive stromal, endothelial and macrophage populations export extracellular vesicles carrying oxidized mtDNA fragments and the transferable second messenger 2'3'-cGAMP, which are engulfed by CX3CR1+ microglia and install STING-dependent senescence horizontally, without any soluble hormone entering the brain. Brain senescence is therefore transmitted, not locally generated, which is why it precedes and is independent of estradiol level and why clearing or removing the senescent ovary — rather than replacing hormones — reverses it. Mechanism: Ovarian ageing precedes systemic ageing in females, and EV output from the ovary rises steeply as follicle reserve collapses. Because cGAMP acts directly on STING, EV-delivered cGAMP and ox-mtDNA bypass the requirement that the recipient cell first sustain its own mitochondrial lesion — the key feature that makes horizontal induction possible and makes the ovary a sufficient source rather than a correlated bystander. EVs reach brain via receptor-mediated transcytosis and the midlife-leaky hippocampal microvasculature and are preferentially taken up by microglia, activating STING→TBK1→IRF3 and NF-κB. Microglial SASP then imposes bystander senescence on astrocytes and OPCs, blocking OPC differentiation and remyelination, while sustained interferon tone drives DRP1-dependent mitochondrial fission and complex I inefficiency in neurons — a MiDAS-like state that is the proximate cause of hypometabolism and of tau-biased vulnerability at equal amyloid burden. Sex specificity and timing coincide at STING: X-linked CGAS and escape-from-XCI interferon genes set receiver gain, while follicle-reserve collapse sets the moment of maximal sender output. Prediction: EVs purified from mid-depletion VCD mouse ovary, or from human early-perimenopausal plasma, injected into young intact females are sufficient to produce hippocampal p16/γH2AX, microglial interferon signature and memory deficits at normal estradiol. The effect is abolished by microglia-restricted Cgas or Sting1 deletion in recipients, by senolytic (dasatinib+quercetin) clearance of donor ovaries before EV harvest, and by ENPP1 pretreatment that hydrolyses EV cGAMP — three independent cuts that no hormone-withdrawal or FSH model predicts. Conversely, midlife ovariectomy or ovarian senolysis, but not estradiol replacement, prevents and partially reverses the brain phenotype; donor-derived EV cargo should be traceable in recipient microglia, and in staged human cohorts plasma EV cGAMP and ox-mtDNA should peak in early perimenopause and predict GFAP, p-tau217 and FDG hypometabolism better than any hormone.

• GPT-5.6 Solmatch score 2compatible with the reference findingplausibility 2 of 5

  It proposes peripheral vesicle-mediated induction of brain senescence but replaces the splenic RBMX–miR-10a-5p–γCaMKII axis with an ovarian cGAMP/mtDNA–STING mechanism. The EV transfer chain is highly speculative, and the claim that cGAS is X-linked is incorrect.

• Grok 4.7match score 2compatible with the reference findingplausibility 3 of 5

  The proposal addresses the same female midlife peripheral-to-brain phenotypes of senescence, mitochondrial dysfunction and memory loss, but assigns them to ovarian EV ox-mtDNA and cGAMP activating microglial STING. That route can operate alongside splenic RBMX-dependent miR-10a-5p repression of γCaMKII; ovary-to-brain cGAMP transfer as a hormone-independent sufficient cause remains speculative.

• Gemini 4 Argon (medium)match score 2compatible with the reference findingplausibility 3 of 5

  Like the published finding, P1 proposes a circulating vesicle/nucleic-acid-mediated peripheral-to-brain signal during female midlife, but it identifies ovarian cGAMP/ox-mtDNA and microglial STING rather than splenic RBMX–miR-10a-5p–γCaMKII. While testable, long-range delivery of intact cGAMP via ovarian EVs across the blood-brain barrier in sufficient quantities to directly trigger microglial STING is speculative.

Aged myocardium suffers mitophagy over-initiation into a bandwidth-limited lysosomal channel: Parkin/BNIP3 elevation increases backlog noise and secondary membrane injury, whereas sink-only opening (TFEB nuclear entry, V-ATPase acidification) restores fidelity and reverses cardiac aging hallmarks. Mechanism: Lysosomal hydrolase and acidification capacity is the finite-rate bottleneck; upstream tagging continues or rises with stress, converting initiation into mitophagosome backlog, cathepsin leak, and further mitochondrial killing—an initiation-flood / blocked-pipe cascade. Prediction: Parkin or BNIP3 overexpression in aged hearts will worsen mt-Keima acidic delivery and raise lysosomal membrane permeability; TFEB activation or lysosomal re-acidification without changing initiation markers will restore flux, shrink mtDNA mosaicism, and improve ejection fraction, falsifying initiation-deficit models.

• GPT-5.6 Solmatch score 3compatible with the reference findingplausibility 4 of 5

  It captures the key concept that excessive BNIP3-associated mitophagy initiation can congest downstream flux and drive cardiac dysfunction. However, it omits HIF-3α, mitochondrial transplantation, and ATP homeostasis, and assigns primary causality and rescue to lysosomal capacity rather than the published upstream signaling axis.

• Claude Opus 5.5match score 3compatible with the reference findingplausibility 4 of 5

  It correctly identifies the core phenomenon — mitophagy over-initiation with elevated BNIP3 producing flux congestion rather than an initiation deficit — but attributes the bottleneck to finite lysosomal capacity and proposes TFEB/acidification rescue, missing HIF-3α as the driver and mitochondrial transplantation/ATP restoration as the intervention.

• Gemini 4 Argon (medium)match score 3compatible with the reference findingplausibility 5 of 5

  Correctly identifies the core mechanism of BNIP3 elevation and mitophagy over-initiation causing flux congestion/backlog in aged cardiomyocytes, but misses the upstream HIF-3α regulator and proposes lysosomal sink activation rather than mitochondrial transplantation and ATP restoration.

Under a fixed recipient diet and physiological state, viable gut microbial communities from older human donors more frequently cause persistent intestinal barrier dysfunction, impaired glucose regulation, and inflammatory mucosal transcription than communities from younger donors. This transmissible effect depends on engrafted microbial functions and varies among donors within each age group. Mechanism: Persistent microbial colonisation changes local metabolite production and inflammatory microbial-product exposure, altering epithelial maintenance and mucosal immune activity. These changes increase intestinal permeability and disrupt systemic metabolic regulation. Prediction: In randomised transfers using multiple independent donors balanced for major dietary, medication, and disease factors, washed viable older-donor communities cause greater tracer permeability, ex vivo epithelial flux, and impaired insulin action than younger-donor communities. Effects persist beyond clearance of inoculum-derived soluble material, accompany within-cell mucosal transcriptional changes, and are not persistently reproduced by matched nonviable inocula or single sterile-filtrate transfers. Donor-level effects track engrafted microbial functions more closely than chronological age; absence of a reproducible age-group difference would reject the age-associated claim even if individual communities remain harmful.

• Grok 4.7match score 3compatible with the reference findingplausibility 4 of 5

  It states the central causal result that engrafted older-donor communities impair barrier function, systemic metabolic regulation, and mucosal transcription, while leaving out Tyr-Phe, prostaglandin E3, the seven antiviral hub genes, and Blautia. That colonization claim can hold together with those molecular details and is a credible, directly testable answer to the causality question.

• Claude Opus 5.5match score 4compatible with the reference findingplausibility 5 of 5

  Captures the central causal claim — viable older-donor communities transmissibly impair barrier function, systemic metabolism and mucosal transcription, mediated by engrafted metabolite production — and is carefully testable; it lacks the specific mediators (Tyr-Phe, PGE3, the seven hub genes, Blautia obeum) and frames mucosal transcription as inflammatory rather than suppressed antiviral programmes.

• Gemini 4 Argon (medium)match score 3compatible with the reference findingplausibility 5 of 5

  Correctly captures the central causal claim that transplanting older-donor human gut microbiota impairs intestinal barrier function, systemic metabolism, and mucosal transcription via altered metabolites, but misses the specific mediators (Tyr-Phe, PGE3, Blautia obeum) and antiviral gene signature. It represents a strong, well-founded experimental framework.

A commensal microorganism prioritized through causal mediation and network integration of multi-modal human ageing profiles—combining shotgun metagenomics, circulating and fecal metabolomics, immune phenotyping, clinical organ parameters, and biological ageing clocks—causally extends lifespan and multi-system healthspan across evolutionarily divergent hosts (*Caenorhabditis elegans*, *Drosophila melanogaster*, and naturally aged mice). Administration of this human-nominated commensal coordinately shifts aged multi-organ transcriptomic, epigenetic, and metabolomic profiles, alongside the resident gut microbiome ecosystem, toward configurations characteristic of younger individuals. This geroprotective activity depends on conserved microbial metabolic pathways that remain active across host species rather than cohort-specific dietary or environmental confounding. Mechanism: Multi-omic causal inference (Mendelian randomization, directional mediation analysis, and longitudinal mixed-effects network modeling) across heterogeneous human cohorts isolates specific age-depleted commensal taxa whose functional gene pathways directly mediate lower biological age clocks and preserved organ function independent of diet, polypharmacy, and frailty. Upon oral administration to aged model organisms, the predicted commensal engrafts or transiently metabolizes luminal substrates to restore youthful host-microbe signaling, reactivating conserved intracellular longevity regulators—specifically AMPK/ULK1-driven autophagy, mitochondrial oxidative phosphorylation, and intestinal tight-junction maintenance—while suppressing systemic senescence-associated secretory phenotype (SASP) and innate immune hyperactivation across metabolic, musculoskeletal, neural, and hematopoietic tissues. Concurrently, the organism acts as an ecological stabilizer in the aged gut by cross-feeding endogenous strict anaerobes (e.g., butyrate-producing *Oscillospiraceae* and *Lachnospiraceae*) and maintaining luminal hypoxia to competitively exclude age-enriched facultative pathobionts (*Enterobacteriaceae*). Prediction: In *C. elegans*, *Drosophila*, and naturally aged C57BL/6 mice (initiated at 16–18 months of age), supplementation with the top causally nominated human commensal reproducibly extends median and maximum lifespan, lowers composite frailty indices, improves glucose homeostasis, neuromuscular coordination, and intestinal barrier integrity, and shifts multi-tissue DNA methylation and transcriptomic clocks (across liver, skeletal muscle, brain, and colon) as well as fecal microbial co-abundance networks toward a young reference state; in contrast, administration of an age-neutral commensal, a taxon correlated with chronological age solely via dietary confounding, or an isogenic mutant strain lacking the computationally prioritized metabolic pathway fails to extend longevity or rejuvenate systemic molecular and microbial states.

• GPT-5.6 Solmatch score 3compatible with the reference findingplausibility 3 of 5

  Matches the broad concept that an integrated human multi-omic analysis can nominate a commensal that extends lifespan and healthspan and rejuvenates aged molecular and microbial profiles. It fails to identify N. flavescens, distinguish live C. elegans treatment from heat-killed mouse treatment, or mention confirmed metabolite production, while adding unsupported effects in Drosophila, mouse lifespan, engraftment, epigenetic clocks, and specific pathways.

• Grok 4.7match score 3compatible with the reference findingplausibility 4 of 5

  The hypothesis recovers human multi-omic nomination, dependence on microbial metabolic pathways, C. elegans lifespan extension, and a shift of aged mouse molecular and microbiome states toward a younger configuration. It leaves the causal species and the heat-killed mouse regimen unspecified and adds Drosophila, mouse lifespan, and epigenetic clocks, which the finding does not establish and does not refute.

• Claude Opus 5.5match score 3compatible with the reference findingplausibility 3 of 5

  Correctly frames the pipeline from integrated human ageing profiles to a causally nominated commensal that extends lifespan in worms and rejuvenates multi-omic and microbial states in aged mice, but it names no organism, omits the live/heat-killed contrast, and adds Drosophila and mouse lifespan extension not shown.

A bispecific T-cell engager targeting uPAR (PLAUR) on senescent cells and CD3 on T cells will clear senescent cells in aged mice and non-human primates, with titratable dosing because engager occupancy and the resulting cytolytic synapse number scale with circulating drug concentration. Efficacy appears as reduced senescence burden plus improved metabolic and physical function; toxicity appears as on-target clearance of uPAR-expressing myeloid and endothelial compartments. Mechanism: uPAR is a cell-surface antigen broadly upregulated on senescent cells across tissues; a short-half-life CD3 bispecific redirects endogenous cytotoxic T cells to lyse uPAR-high cells via perforin/granzyme, and because the engager is a reversible bridge rather than a persistent engineered cell, exposure and therefore senolysis depend continuously on dose and can be stopped. Prediction: Dose-response in both species shows a window where p16/p21-high and uPAR-high cells fall by >50% and grip strength/glucose tolerance improve, while below-threshold doses do nothing and above-threshold doses cause cytokine elevation and hepatic/endothelial injury — and the window is reproducible when dosing is scaled by exposure (AUC), not body weight.

• GPT-5.6 Solmatch score 4compatible with the reference findingplausibility 5 of 5

  It closely reproduces the central finding: a dose-titratable uPAR-CD3 engager clears senescent cells in mice and non-human primates, improves age-related phenotypes, and causes hepatic or endothelial injury at excessive exposure. It omits serum aminotransferase monitoring as the practical safety marker and adds some unestablished specifics.

• Grok 4.7match score 4compatible with the reference findingplausibility 5 of 5

  This states the central result: a uPAR–CD3 T-cell engager gives exposure-dependent senolysis and functional benefit in aged mice and non-human primates, with high-dose hepatic/endothelial injury. It omits serum aminotransferase as the safety guide and broadens toxicity to myeloid cells, but the uPAR bispecific mechanism is well supported and consistent with the finding.

• Gemini 4 Argon (medium)match score 4compatible with the reference findingplausibility 5 of 5

  P3 accurately identifies the uPAR-CD3 bispecific T-cell engager, its dose-dependent senolytic efficacy and functional benefits in aged mice and non-human primates, and high-dose hepatic endothelial toxicity, missing only serum aminotransferases as the specific safety biomarker (proposing drug exposure/AUC instead). It is strongly grounded in established senescence biology and bispecific antibody pharmacology.

Soluble α-Klotho (sKL) is a causal, age-declining regulator of cognition that acts without entering the brain parenchyma: it signals to megakaryocytes/platelets in the periphery, and the resulting release of platelet factor 4 (PF4) is the obligate relay that lowers hippocampal senescence burden and interferon-driven neuroinflammation. Restoring sKL in aged mice therefore improves memory only while platelet-derived PF4 signalling is intact, and the sKL effect size should scale with the induced rise in plasma PF4 rather than with brain sKL exposure. Mechanism: Age-related fall in sKL (kidney/choroid-plexus shedding) removes a tonic peripheral signal. Exogenous sKL engages a surface receptor complex on megakaryocytes/platelets (FGFR1c-dependent but FGF23-independent, testable by FGFR1c blockade and by FGF23-neutral dosing), driving α-granule release of PF4. Circulating PF4 acts at the brain interface — on cerebrovascular endothelium and, via CXCR3 on microglia, on parenchymal microglia — to damp the aged microglial type-I interferon programme. Lower IFN tone reduces cGAS–STING/TBK1–IRF3 and NF-κB output, which is the shared node: SASP cytokines (IL-6, IL-1β, CXCL10) fall, and paracrine induction of p16INK4a/p21 in oligodendrocyte precursors, astrocytes and endothelium declines. Downstream consequences are restored dentate-gyrus neurogenesis and recovered GluN2B-dependent synaptic plasticity, giving the behavioural gain. Because the entry step is peripheral, the hypothesis predicts a two-compartment pharmacology: short plasma sKL exposure, delayed and longer-lasting central change. Prediction: A single peripheral sKL dose raises plasma PF4 dose-dependently and improves Barnes-maze/novel-object performance in aged wild-type mice, but gives no cognitive, p16-burden or hippocampal interferon-gene benefit in Pf4-null mice, in platelet-depleted aged mice, or in Cxcr3 microglia-conditional knockouts — while brain sKL remains undetectable in all arms. A competing direct-brain-action model predicts the benefit survives Pf4 deletion; a non-specific 'plasma protein' model predicts no PF4 dose–response relationship.

• GPT-5.6 Solmatch score 2compatible with the reference findingplausibility 3 of 5

  It addresses age-related cognition, microglial inflammation and senescence but substitutes the sKL–PF4 pathway for ghrelin and the SHBG/JNK1/Beclin1 autophagy axis. The peripheral sKL–platelet–PF4 relay is biologically motivated, but the proposed receptor, CXCR3 dependence and downstream senescence chain remain speculative.

• Grok 4.7match score 2compatible with the reference findingplausibility 4 of 5a suitable alternative mechanism

  This assigns the cognitive, senescence, and interferon benefit to peripheral soluble Klotho acting through platelet PF4 and microglial CXCR3, not to ghrelin or SHBG/JNK1/Beclin1 autophagy. That pathway can coexist with ghrelin signalling, and Klotho plus PF4 biology makes the relay a specific, testable account.

• Gemini 4 Argon (medium)match score 2compatible with the reference findingplausibility 5 of 5a suitable alternative mechanism

  Proposes a different circulating regulator (soluble α-Klotho via PF4) and downstream signaling pathway (CXCR3/cGAS-STING) rather than ghrelin and the SHBG/JNK1/Beclin1 autophagy axis, though it shares the focus on microglial inflammation and senescence. The sKL-PF4 axis is strongly supported by recent ageing literature and provides a specific, testable hypothesis that can coexist with ghrelin's mechanism.

Age-dependent uncoupling of endothelial PDGF-BB/PDGFRbeta and Angiopoietin-1 (Ang-1)/Tie2 signaling, coupled with local Angiopoietin-2 (Ang-2) and TGF-beta1 upregulation, drives strial pericyte detachment and Smad2/3-dependent transdifferentiation into matrix-depositing myofibroblasts. The resulting basement membrane lamination and focal hypoxia activate endothelial RhoA/ROCK contractility and VEGF-A/VEGFR2-c-Src-mediated VE-cadherin phosphorylation, unzipping intercellular junctions to cause microvascular rarefaction, BLB leakage, and metabolic presbycusis. Mechanism: Strial capillaries depend on an exceptionally high density of PDGFRbeta+/NG2+/Desmin+ pericytes to stabilize the intrastrial fluid-blood barrier. With advancing age, endothelial oxidative stress reduces PDGF-BB secretion and upregulates the competitive Tie2 antagonist Ang-2 alongside latent TGF-beta1 activation. Diminished PDGFRbeta and Tie2 phosphorylation weakens pericyte-endothelial N-cadherin and EphrinB2/EphB4 adhesions, causing pericytes to detach from the shared capillary wall and undergo TGF-beta1/ALK5/Smad2/3-driven transition into alpha-SMA+/Collagen-I+/Fibronectin+ myofibroblast-like cells. These transdifferentiated cells deposit excessive cross-linked extracellular matrix that causes basement membrane thickening, lamination, and capillary lumen narrowing, inducing focal strial ischemia and stabilizing HIF-1alpha in marginal and intermediate cells. In strial endothelial cells, withdrawal of tonic Ang-1/Tie2-PI3K/Akt signaling synergizes with hypoxia-induced paracrine VEGF-A/VEGFR2 activation through two converging pathways: (1) de-repression of RhoA and ROCK1/2 phosphorylates myosin light chain (p-MLC2) to generate centripetal actomyosin stress-fiber tension, and (2) VEGFR2-recruited c-Src phosphorylates VE-cadherin at Tyr658 and Tyr685, disrupting p120-catenin binding and triggering clathrin-mediated VE-cadherin internalization followed by ubiquitin-proteasomal degradation of ZO-1 and Claudin-5. Progressive pericyte loss leaves acellular capillaries and open paracellular clefts that leak serum proteins into the intrastrial space, causing bioenergetic exhaustion of marginal cell Na+/K+-ATPase pumps, EP depolarization, and secondary outer hair cell and spiral ganglion neuron degeneration. Prediction: High-resolution whole-mount confocal imaging, transmission electron microscopy, and phospho-proteomics of aging mouse stria vascularis will reveal pericyte detachment, alpha-SMA/Col1a1 upregulation, and endothelial VE-cadherin Tyr658/Tyr685 phosphorylation occurring prior to overt endothelial cell death or PVMM loss. Inducible pericyte-specific deletion of Tgfbr2 (Pdgfrb-CreERT2;Tgfbr2fl/fl) or pharmacological Tie2 activation (AKB-9778) combined with knock-in of non-phosphorylatable VE-cadherin (Cdh5-Y658F/Y685F) in aged mice will prevent pericyte-to-myofibroblast transition, suppress endothelial p-MLC2 accumulation, preserve continuous Claudin-5/ZO-1 junctional belts, block macromolecular tracer leakage, and preserve EP and distortion product otoacoustic emissions (DPOAEs), whereas inhibiting PVMM inflammasomes or ferroptosis alone will not prevent barrier breakdown if pericyte detachment and Tie2/Src dysregulation persist.

• GPT-5.6 Solmatch score 3compatible with the reference findingplausibility 4 of 5

  It correctly centers TGF-β/Smad-dependent strial pericyte switching, barrier disruption, and auditory dysfunction, but replaces the demonstrated IGF-1–SLC25A33–mitochondrial ROS trigger with PDGF-BB/Tie2 dysregulation and hypoxia. Pericyte detachment, TGF-β-driven transition, and endothelial junction destabilization form a credible, testable vascular mechanism.

• Grok 4.7match score 3compatible with the reference findingplausibility 4 of 5

  This hits the finding’s effector module—strial pericytes, TGF-β/Smad2/3 phenotypic switching, basement-membrane remodeling, BLB leakage, and hearing loss—while casting the ageing trigger as PDGF-BB/Tie2 uncoupling and Ang-2 rather than IGF-1–SLC25A33–mtROS. Those vascular signals can operate together with the IGF-1 pathway and rest on solid pericyte biology.

• Claude Opus 5.5match score 3compatible with the reference findingplausibility 4 of 5

  Correctly centers strial pericytes undergoing TGF-β/Smad2-3-dependent phenotypic switching that breaks the blood-labyrinth barrier, matching the downstream half of the finding, but attributes the upstream trigger to PDGF-BB/Ang-1-Tie2 uncoupling rather than IGF-1 loss and SLC25A33-dependent mitochondrial ROS. Pericyte-endothelial signaling withdrawal in the aged stria is well supported, making this a credible and largely co-existing account.

Direct allosteric activation of AMP-activated protein kinase (AMPK; Snf1/AAK-2/dAMPK) at the conserved alpha/beta-subunit Allosteric Drug and Metabolite (ADaM) interface is sufficient to extend lifespan across evolutionarily diverse invertebrates and induce caloric-restriction-like metabolic, vascular, and transcriptomic rejuvenation in mammals without perturbing cellular energy charge. These cross-species longevity benefits depend strictly on intact drug-pocket binding and a conserved downstream catabolic module comprising ULK1/Atg1-mediated mitophagy and acetyl-CoA carboxylase (ACC)-regulated fatty acid beta-oxidation. Furthermore, preferential engagement of beta1-containing heterotrimers in central metabolic tissues elicits systemic mammalian healthspan benefits while avoiding the cardiac glycogen accumulation associated with chronic pan-beta hyperactivation. Mechanism: Selective small-molecule ADaM-site agonists (such as 991, O304/ATX-304, MK-8722, and beta1-selective PF-06409577) bind directly to the hydrophobic cleft between the alpha-subunit kinase domain and the beta-subunit carbohydrate-binding module (CBM), centering on the phosphorylated beta-Ser108 residue. This binding stabilizes the active heterotrimeric conformation, allosterically stimulates catalytic activity, and protects activation-loop Thr172 from phosphatases without inhibiting mitochondrial Complex I or altering intracellular AMP:ATP and ADP:ATP ratios. Activated AMPK directly phosphorylates ULK1 (Atg1) and Raptor/TSC2 to suppress mTORC1 and trigger autophagic/mitophagic clearance of dysfunctional mitochondria, phosphorylates ACC1/ACC2 to lower malonyl-CoA and promote CPT1-dependent fatty acid beta-oxidation, and activates FOXO/DAF-16 and PGC-1alpha transcriptional networks alongside endocrine hepatokine (FGF21/GDF15) secretion in mammals. Prediction: ADaM-site activators will extend replicative and chronological survival in S. cerevisiae, C. elegans, and D. melanogaster and reverse age-associated insulin resistance, hepatic steatosis, microvascular rarefaction, and pro-inflammatory transcriptomic signatures in aged M. musculus without reducing cellular ATP or mitochondrial oxygen consumption at Complex I. Crucially, both invertebrate lifespan extension and mammalian metabolic remodeling will be completely abolished in catalytic nulls (e.g., C. elegans aak-2 deletion), in knock-in animals or cells carrying the drug-insensitive allosteric point mutation AMPK-beta S108A that preserves basal AMP-responsive kinase activity, and upon genetic blockade of downstream ULK1/Atg1 mitophagy or CPT1/ACC-regulated beta-oxidation, whereas beta1-selective agonists will recapitulate systemic metabolic rejuvenation without increasing cardiac glycogen content or heart-to-body-weight ratio.

• GPT-5.6 Solmatch score 4compatible with the reference findingplausibility 3 of 5

  It most closely matches the finding by naming 991, direct activation at the AMPK ADaM interface, lifespan extension in worms and flies, and pro-longevity molecular remodeling in mice. It names S. cerevisiae rather than S. pombe and adds numerous compounds, phenotypes, endocrine mechanisms, and absolute genetic dependencies that are plausible in parts but not established as a unified causal mechanism.

• Grok 4.7match score 4compatible with the reference findingplausibility 4 of 5

  It states the central causal result: direct ADaM-site activation by 991 extends lifespan across diverse species and induces pro-longevity remodeling in mice without altering energy charge. The main secondary miss is budding yeast instead of S. pombe, with physiological and transcriptomic endpoints in place of the mouse proteomic profile; the extra absolute requirement for both mitophagy and fatty-acid oxidation is narrower than the evidence.

• Claude Opus 5.5match score 5compatible with the reference findingplausibility 5 of 5

  States the same causal finding: direct ADaM-site allosteric AMPK activation (explicitly naming 991) extends lifespan in yeast, worms and flies without altering energy charge, and drives pro-longevity metabolic/transcriptomic remodeling in mice, with conserved downstream effectors and drug-pocket-dependence tests; the added beta1-selectivity/cardiac-safety claims are plausible extensions rather than contradictions.

Stress-activated sympathetic fibers co-release neuropeptide Y into the marrow niche; NPY via Y1 receptors on stromal cells induces mitochondrial dysfunction and a senescence-associated secretory phenotype that impairs osteoblastogenesis. Non-invasive sensory or autonomic peripheral stimulation restores osteogenesis by suppressing NPY release or upregulating competing osteogenic neuropeptides such as CGRP. Mechanism: Sympathetic NPY → Y1R → mitochondrial ROS/SASP in marrow stroma → osteogenic failure Prediction: Y1 receptor antagonism or NPY deletion will prevent stress-induced senescence without normalizing norepinephrine levels, and peripheral stimulation efficacy will correlate with reduced marrow NPY and elevated CGRP rather than with β-adrenergic tone alone.

• GPT-5.6 Solmatch score 3compatible with the reference findingplausibility 4 of 5

  It captures the central roles of sympathetic NPY, Y1R-dependent marrow-cell senescence, impaired osteogenesis, and peripheral suppression of NPY. It misses marrow adipocytes as the specific target and the sensory nerve-semaphorin 3A circuit, while introducing unsupported CGRP and mitochondrial details.

• Claude Opus 5.5match score 4compatible with the reference findingplausibility 5 of 5

  Captures the central claim: sympathetic NPY acting via Y1R induces senescence/SASP in marrow stroma to block osteoblastogenesis, reversible by peripheral stimulation that lowers NPY independently of adrenergic tone; it says stromal cells rather than specifically adipocytes and proposes CGRP instead of semaphorin 3A as the sensory mediator.

• Gemini 4 Argon (medium)match score 3compatible with the reference findingplausibility 5 of 5

  Correctly identifies the core causal mechanism—sympathetic NPY acting via Y1 receptors to induce marrow senescence and sensory nerve stimulation suppressing local NPY release—but specifies stromal cells broadly rather than adipocytes and misses PEMF-induced Sema3A as the sensory mediator. It is strongly grounded in neuro-skeletal biology and directly testable.

Pathological tethering of mitochondria-associated ER membranes (MAMs) via the IP3R-GRP75-VDAC1-MCU complex drives mitochondrial calcium overload, bioenergetic collapse, and premature senescence in localized scleroderma fibroblasts. Pharmacological disruption of ER-mitochondria calcium transfer prevents fibroblast senescence and ameliorates dermal fibrosis. Mechanism: Upregulation of MAM tethering proteins (PACS2, Mitofusin-2, and the IP3R-GRP75-VDAC1 bridge) in lesional fibroblasts increases physical apposition between the ER and mitochondria, channeling excessive Ca2+ from the ER lumen into the mitochondrial matrix via the mitochondrial calcium uniporter (MCU). Matrix Ca2+ overload induces mitochondrial permeability transition pore (mPTP) opening, cristae remodeling, and bursts of superoxide that cause telomeric and genomic DNA damage response (DDR) activation (γH2AX-ATM-p53-p21), driving senescence and TGF-β-dependent fibrogenesis. Pharmacological inhibition of MCU (Ru360), VDAC1 oligomerization (VBIT-4), or IP3R (2-APB) uncouples inter-organelle Ca2+ flux and halts senescence-driven fibrosis. Prediction: High-resolution imaging and proximity ligation assays in localized scleroderma fibroblasts will reveal increased IP3R-VDAC1 contact sites and elevated mitochondrial matrix Ca2+ preceding senescence onset, and selective inhibition of MCU or VDAC1 will prevent mtROS generation, DDR activation, and dermal thickening.

• GPT-5.6 Solmatch score 3compatible with the reference findingplausibility 4 of 5

  It identifies the key MAM calcium-transfer complex and connects its dysregulation to mitochondrial damage, senescence, and fibrosis, but omits Ero1L, parthenolide, ARG-449, and the decisive Ero1L gain- and loss-of-function evidence. Aberrant ER–mitochondrial calcium transfer is a strong, specific, and testable mechanism, though the proposed direction of MAM tethering and individual inhibitor effects require validation.

• Grok 4.7match score 3compatible with the reference findingplausibility 4 of 5

  The hypothesis correctly centers on IP3R–GRP75–VDAC1 MAM contacts and mitochondrial calcium overload as the route to mitochondrial damage, senescence, and fibrosis, while leaving out Ero1L causality and parthenolide binding at ARG-449 and adding MCU and other tethers. Those additions can lie on the same axis, and ER–mitochondria calcium transfer is a specific, well-supported mechanism.

• Claude Opus 5.5match score 4compatible with the reference findingplausibility 5 of 5

  Centers on exactly the IP3R-Grp75-VDAC1 MAM calcium axis causing mitochondrial damage, senescence and fibrosis, and proposes pharmacological disruption; it misses Ero1L as the upstream driver and parthenolide as the agent, and frames excess tethering as pathological where the finding frames normalization of MAM function.

Priming is a receptor-level gate: mechanical injury and ageing up-regulate AT1R (and down-regulate the protective AT2R/ACE2–Mas arm) in chondrocytes and subchondral osteoblasts, and mechanical stretch activates AT1R in a ligand-independent way. Only after this shift do joint cells respond to circulating angiotensin II, which explains why hypertension damages predisposed joints and spares healthy ones. Mechanism: Stretch- and ageing-induced NF-kB/YAP and Piezo1-dependent signalling raises Agtr1a transcription while oestrogen loss and senescence reduce ACE2/AT2R counter-regulation. The resulting high AT1R density lets the same plasma angiotensin II concentration produce a much larger ROS/p38/NF-kB output, and stretch-activated AT1R adds a ligand-free component, so injury and hypertension converge on one receptor and act multiplicatively rather than additively. Prediction: AT1R protein and Agtr1a mRNA rise in cartilage and subchondral bone within 1–2 weeks after DMM and with age, with a reciprocal fall in AT2R/ACE2; angiotensin II then causes large catabolic responses in injured or aged explants and near-none in young intact explants at identical doses. A statistical interaction term (injury x hypertension) on OARSI score should be significant, and an AT1R mutant insensitive to stretch but responsive to ligand (or a biased blocker) should separate the two activation routes. Ovariectomy should amplify the gate.

• GPT-5.6 Solmatch score 2contradicts the reference findingplausibility 3 of 5

  It captures the receptor-level priming concept and interaction between hypertension and predisposed joints, but identifies AT1R rather than up-regulated AVPR1A and omits AVP and NR4A3. The assertion that injury and hypertension converge on one AT1R pathway conflicts with the published causal receptor, while ligand-independent AT1R activation and the proposed receptor shift remain plausible but speculative.

• Grok 4.7match score 3compatible with the reference findingplausibility 4 of 5

  This captures the core gating logic that ageing or injury upregulates a chondrocyte receptor so a circulating hypertensive hormone drives catabolism only in primed joints, while naming AT1R, angiotensin II and ROS–NF-κB instead of AVPR1A, AVP and NR4A3. An AT1R priming gate could exist in parallel and is a coherent, testable alternative.

• Gemini 4 Argon (medium)match score 2compatible with the reference findingplausibility 4 of 5a suitable alternative mechanism

  P5 correctly identifies the core conceptual architecture—that injury/aging primes chondrocytes by up-regulating a vasoactive peptide GPCR to gate responses to a circulating hypertension-associated hormone—but identifies AngII/AT1R instead of AVP/AVPR1A. Unlike P1, it does not make exclusive claims that rule out parallel or dominant AVPR1A gating, making it compatible in principle and biologically plausible.

Hyper-glycemic, amino-acid-replete ex vivo expansion imprints adoptively transferred immune cells with constitutive mTORC1 activity, suppressed mitophagy, and low mitochondrial spare respiratory capacity (SRC), rendering them unable to buffer ATP demand when CAR or TCR signaling encounters intratumoral glucose scarcity. The resulting surge in the intracellular AMP:ATP ratio triggers non-canonical AMPKα–TAB1–p38α MAPK scaffold assembly and p38α autophosphorylation, which represses telomerase (hTERT), induces p16INK4a/p21CIP1 arrest, and drives shedding and transcriptional silencing of CD27 and CD28. Loss of CD28/CD27 costimulation collapses NF-κB and PI3K–AKT survival signaling (BCL-2, BCL-xL, and autocrine IL-2), causing senescent cells to undergo rapid BIM/BAX-dependent apoptosis in vivo. Mechanism: Standard ex vivo manufacturing in high glucose (11–25 mM) and mitogenic cytokines drives sustained mTORC1–S6K1 activity, which inhibits ULK1-dependent mitophagy (via Ser757 phosphorylation) and represses FOXO1/PGC-1α-mediated mitochondrial biogenesis, generating glycolytically addicted effector cells with fragmented mitochondria and minimal oxidative SRC. Upon transition into a glucose-depleted solid tumor (<0.5 mM glucose), continuous ATP hydrolysis fueled by tonic or antigen-engaged CAR/TCR signaling and cytoskeletal remodeling rapidly outstrips oxidative phosphorylation, causing an acute spike in intracellular AMP:ATP and ADP:ATP ratios. AMP-bound, Thr172-phosphorylated AMPKα binds the scaffold protein TAB1 to nucleate a ternary complex with p38α MAPK, inducing MKK3/6-independent cis-autophosphorylation of p38α at Thr180/Tyr182. Active TAB1–p38α translocates to the nucleus to inhibit MYC/SP1-dependent TERT transcription and telomerase activity while inducing p53, p21CIP1, and p16INK4a. Concurrently, p38α activates membrane sheddases (ADAM10/17) and transcriptionally silences CD27 and CD28. Stripped of CD28/CD27 costimulatory input, transferred cells lose canonical NF-κB (RelA/p50) and PI3K–AKT pro-survival transcription of BCL2, BCL2L1 (BCL-xL), and autocrine IL2, unleashing unopposed BIM/BAX mitochondrial outer membrane permeabilization and apoptotic clearance. Prediction: Engineering CAR-T cells with a knock-in point mutation or peptide inhibitor that selectively disrupts the TAB1–p38α binding interface (sparing canonical MKK3/6–p38α signaling required for IFN-γ/TNF-α production)—or pre-conditioning cells ex vivo with inosine and transient mTORC1/glycolysis inhibition to elevate PGC-1α and mitochondrial SRC—will prevent intratumoral p38α autophosphorylation, preserve hTERT activity and surface CD27/CD28, maintain BCL-2/BCL-xL expression, and sustain long-term in vivo persistence and serial tumor killing even under severe glucose restriction. Furthermore, forced expression of BCL-xL or a constitutive intracellular CD28 costimulatory domain in TAB1–p38α-active cells will rescue intratumoral survival without restoring telomerase activity or proliferation, directly uncoupling p38α-mediated cell-cycle arrest from costimulation-loss-driven apoptotic attrition.

• GPT-5.6 Solmatch score 3compatible with the reference findingplausibility 3 of 5

  It correctly identifies glucose scarcity as activating AMPK and driving senescence and impaired persistence, but substitutes TAB1–p38α and costimulation-dependent apoptosis for the reported ZAK–NIK suppression of noncanonical NF-κB and IL-9. The metabolic premise is credible, but the detailed AMPK–TAB1–p38α, telomerase, and CD27/CD28 chain is insufficiently established in this setting.

• Grok 4.7match score 3compatible with the reference findingplausibility 4 of 5

  Glucose scarcity is correctly linked to AMPK activation and senescence of transferred T cells, but the effector arm is TAB1–p38, CD27/CD28 loss, and BIM/BAX apoptosis, omitting ZAK–NIK suppression of noncanonical NF-κB and IL-9. AMPK–TAB1–p38 T-cell senescence is established and can operate together with ZAK–NIK, so this remains a credible alternative effector model.

• Claude Opus 5.5match score 3compatible with the reference findingplausibility 4 of 5

  Correctly centers glucose scarcity and AMPK activation as the initiating signal for senescence in transferred cells, which is the finding's upstream core, but then routes through TAB1–p38α/telomerase/CD28 loss rather than the ZAK–NIK–noncanonical NF-κB–IL-9 axis, and says nothing of Th9/IL-9. AMPK–TAB1–p38 and low spare respiratory capacity are real, well-documented biology, making this a credible competitor.

The age-related loss of fiber-fermenting Lachnospiraceae and Ruminococcaceae depletes systemic short-chain fatty acids (butyrate, propionate, and acetate), causally impairing both early alveolar macrophage interferon priming and influenza-specific CD8+ cytotoxic T lymphocyte (CTL) bioenergetics. This deficit can be counteracted by oral SCFA administration or by direct pharmacological agonism of host free fatty acid receptors GPR41 (FFAR3) and GPR43 (FFAR2) coupled with mitochondrial metabolic activation. Mechanism: Circulating SCFAs signal through FFAR2 and FFAR3 on bone marrow myeloid precursors and lung-resident macrophages to amplify early IFN-beta production and generate Ly6C- patrolling monocytes that limit CXCL1-driven neutrophilic lung damage, while simultaneously entering CD8+ T cells to fuel mitochondrial fatty acid oxidation and HDAC-inhibition-dependent Ifng and Gzmb transcription; SCFA depletion in ageing starves both innate and adaptive effector arms. Prediction: Supplementing aged mice with butyrate/propionate or synthetic FFAR2/FFAR3 agonists during IAV infection will restore early BALF IFN-beta levels, rescue virus-specific NP366/PA224-tetramer+ CD8+ T-cell oxidative phosphorylation, and decrease lung neutrophil infiltration, whereas Ffar2-/- or Ffar3-/- mice will not derive antiviral protection from young FMT or high-fiber diets.

• GPT-5.6 Solmatch score 3compatible with the reference findingplausibility 3 of 5

  It includes age-related SCFA depletion, acetate, and FFAR2/FFAR3, capturing part of the correct mechanism, but centers the intervention on butyrate/propionate and attributes protection to macrophage priming and CD8 T-cell bioenergetics rather than acetate action in senescent fibroblasts with increased histone H3 acetylation. The broader SCFA hypothesis is testable and credible, though several cell-specific mechanistic claims are under-supported.

• Grok 4.7match score 3compatible with the reference findingplausibility 4 of 5

  Naming acetate together with FFAR2/FFAR3 captures the central metabolite and receptor axis and includes reduced neutrophilic inflammation, but equates acetate with butyrate and propionate and shifts protection to macrophage interferon priming and CD8 bioenergetics, omitting senescent-fibroblast viral control and histone H3 acetylation. The model remains compatible with the fibroblast acetate mechanism and is a strong, testable SCFA hypothesis.

• Claude Opus 5.5match score 4compatible with the reference findingplausibility 4 of 5

  Names SCFA depletion including acetate, FFAR2/FFAR3 signaling, and HDAC-inhibition-linked histone acetylation as the counteracting mechanism — the central causal claim matches, though acetate is not singled out and the emphasis on CD8 T-cell bioenergetics rather than reduced viral replication in senescent lung cells blurs one key point.

Senescent muscle stromal cells generate excess ammonia through glutaminolysis, impairing mitochondrial metabolism in neighbouring myofibres and muscle stem cells. Reducing this ammonia burden after dysfunction develops should partially restore muscle respiration, strength and regeneration. Mechanism: Increased glutaminase-dependent glutamine catabolism releases ammonia faster than the local tissue can remove it. Recipient-cell ammonia assimilation redirects glutamate and alpha-ketoglutarate toward nitrogen handling, limiting tricarboxylic-acid-cycle flux and ATP production. Whether ageing muscle reaches ammonia concentrations sufficient to cause this metabolic diversion is an essential unresolved link. Prediction: Senescent-cell glutamine-derived nitrogen should contribute to increased interstitial ammonia and altered recipient-cell nitrogen assimilation before respiratory decline. Selectively reducing stromal glutaminase activity after dysfunction develops should normalize these fluxes and improve ATP-linked respiration and muscle-specific force without reducing senescent-cell abundance. Reinstating the measured local ammonia exposure should abolish rescue; failure of that exposure to reproduce dysfunction would reject ammonia as the mediator.

• Grok 4.7match score 3compatible with the reference findingplausibility 3 of 5

  The proposal identifies senescence-driven glutaminase activity as the driver of mitochondrial impairment, while locating the injury in stromal ammonia release and recipient nitrogen assimilation rather than p38-dependent intracellular urea in myoblasts. A parallel ammonia route remains possible; sufficiency of interstitial ammonia in ageing muscle is speculative.

• Claude Opus 5.5match score 3compatible with the reference findingplausibility 4 of 5

  Correctly identifies senescence-driven glutaminase-dependent glutaminolysis as the causal axis and predicts rescue by reducing glutaminase activity, matching the GLS1 target; however it attributes toxicity to ammonia released to neighbouring cells rather than intracellular urea accumulation within the senescent myoblasts themselves, and omits p38 MAPK.

• Gemini 4 Argon (medium)match score 3compatible with the reference findingplausibility 5 of 5

  Correctly identifies senescence-associated glutaminase (GLS) upregulation and nitrogen-waste toxicity impairing muscle mitochondrial function and strength, as well as rescue by glutaminase inhibition. However, it attributes the downstream toxicity to paracrine ammonia rather than intracellular urea accumulation in myoblasts and omits p38 MAPK signaling.

Time-restricted feeding protects arteries by suppressing NLRP3-inflammasome-driven gasdermin-D pore formation and pyroptosis in endothelial and perivascular myeloid cells; inflammasome activation is the necessary mediator of the accelerated vascular ageing that TRF prevents. Mechanism: The prolonged daily fast lowers postprandial glycemic excursions, lipotoxic DAMPs and mtROS, raises β-hydroxybutyrate (a direct NLRP3 inhibitor) and induces mitophagy, so ASC-speck assembly, caspase-1 activation and IL-1β/IL-18 release fall; less gasdermin-D pore formation preserves endothelial junction integrity, NO bioavailability and prevents the IL-1β→smooth-muscle osteogenic/fibrotic program that stiffens the wall. Prediction: TRF's protection of endothelium-dependent relaxation, pulse-wave velocity and cardiac remodeling is abolished (no further benefit) in Nlrp3−/−, Casp1−/− or Gsdmd−/− animals — i.e. TRF and inflammasome deletion are epistatic, not additive — and conversely constitutively active NLRP3 (Nlrp3^D301N) blocks TRF benefit despite unchanged feeding rhythm; vascular ASC specks and plasma IL-18 fall before any change in blood pressure.

• GPT-5.6 Solmatch score 3compatible with the reference findingplausibility 4 of 5

  It correctly identifies suppression of NLRP3-mediated pyroptosis as a key protective endpoint, but attributes this to fasting metabolites and mitophagy while omitting microbiota-derived acetate, GPR43, HDAC3, H4K8 acetylation, and senescence. These additional inputs into NLRP3 could coexist with the published acetate pathway.

• Grok 4.7match score 3compatible with the reference findingplausibility 4 of 5

  The hypothesis correctly makes NLRP3–caspase-1–gasdermin-D pyroptosis the necessary effector of the vascular ageing that TRF prevents, matching the finding’s downstream target, while the upstream driver is glycemic load, β-hydroxybutyrate, and mitochondrial ROS rather than acetate–GPR43–HDAC3–H4K8ac. That effector relationship can coexist with microbial acetate, and the inflammasome account is a sharp, biologically supported alternative.

• Gemini 4 Argon (medium)match score 3compatible with the reference findingplausibility 5 of 5

  Correctly identifies the suppression of NLRP3 inflammasome-mediated pyroptosis as a critical downstream effector of TRF's vascular protection, but attributes the upstream signal to fasting-induced β-hydroxybutyrate and reduced metabolic DAMPs rather than microbiota-derived acetate, GPR43, and HDAC3/H4K8ac epigenetic remodeling. Both upstream pathways could plausibly operate in parallel to inhibit NLRP3.

Chronic low-dose Tor inhibition preserves lysosomal acidification and autophagic flux during aging, which sustains protein homeostasis and extends lifespan. The benefit depends on maintained lysosomal protease activity rather than reduced protein synthesis alone. Mechanism: Reduced mTORC1 signaling derepresses TFEB/HLH-30 nuclear translocation, upregulating lysosomal biogenesis and v-ATPase subunits, thereby keeping lumenal pH low and clearance competent with age. Prediction: Genetic or pharmacological blockade of TFEB/HLH-30 or v-ATPase will abolish lifespan extension and lysosomal pH preservation under Tor inhibition, while matching the translation-rate reduction without Tor inhibition will not restore lysosomal competence.

• GPT-5.6 Solmatch score 3compatible with the reference findingplausibility 5 of 5

  It captures the TORC1–TFEB/HLH-30–lysosome–autophagy axis and its predicted effects on proteostasis and lifespan, but proposes direct TOR inhibition rather than Rg3 and omits neuronal phosphoinositide remodeling and specific aggregation-toxicity outcomes.

• Claude Opus 5.5match score 4compatible with the reference findingplausibility 5 of 5

  Captures the central causal chain of the finding — TOR/mTORC1 suppression derepressing HLH-30/TFEB nuclear entry to restore lysosomal competence, autophagic flux and proteostasis with lifespan extension. It misses the phosphoinositide remodeling (PI(4)P up, PI(3)P down) and the specific compound, and frames the intervention as generic Tor inhibition rather than Rg3, but the core mechanism is the same and well supported.

• Gemini 4 Argon (medium)match score 3compatible with the reference findingplausibility 5 of 5

  Correctly identifies the core downstream mechanism of TORC1 suppression and TFEB/HLH-30 nuclear translocation preserving lysosomal activity and autophagic flux during aging, but misses the specific upstream intervention (20(S)-ginsenoside Rg3) and neuronal phosphoinositide (PI(4)P/PI(3)P) remodeling. It is a well-established, highly plausible biological mechanism in aging.

In resting naive CD4 T cells, ageing-associated loss of SATB1 disrupts scaffold-associated chromatin loops that spatially segregate selected inflammatory and activation-related promoters from accessible enhancers. Collapse of these loops enables productive enhancer–promoter contacts and lowers the transcriptional threshold for activation. Mechanism: Reduced SATB1 occupancy at scaffold-attachment sequences dismantles a subset of higher-order loop networks without requiring CTCF eviction, prolonged cohesin residence, or lamina detachment. Genes become susceptible when their promoters are released near compatible NF-κB or AP-1 enhancers. Prediction: Acute partial SATB1 depletion in young cells, calibrated to a verified aged-cell deficit, should disrupt SATB1-associated loops before enhancer-contact gains and increased nascent transcription. At an affected locus, inducible bridging of the former scaffold anchors using a system lacking transcriptional effector domains should restore segregation and suppress transcription despite persistent SATB1 deficiency; nonbridging controls should fail. Enhancer silencing should eliminate induction without rebuilding the scaffold loop. Stable CTCF occupancy, cohesin residence, and lamina association would distinguish this mechanism from the previously proposed alternatives.

• Grok 4.7match score 3compatible with the reference findingplausibility 5 of 5

  Age-associated SATB1 loss in resting naive CD4 T cells is correctly identified as causal for enhancer–promoter rewiring and inflammatory and activation transcription without CTCF eviction. The structural intermediate is collapse of SATB1 scaffold loops rather than weakened TAD boundaries and an expanded CTCF interaction range; both descriptions can hold, and SATB1’s established function as a T-cell scaffold organizer makes the claim strong and testable.

• Claude Opus 5.5match score 4compatible with the reference findingplausibility 5 of 5

  Names the correct causal agent — age-associated SATB1 loss dismantling scaffold/loop organization, releasing inflammatory and activation promoters to compatible enhancers — and matches the causal-depletion test; it understates the specific mechanism of relaxed constraint on CTCF-mediated interaction range and TAD boundary weakening, but otherwise captures the central finding.

• Gemini 4 Argon (medium)match score 4compatible with the reference findingplausibility 5 of 5

  Correctly identifies age-associated SATB1 loss in naive CD4+ T cells as the causal driver of enhancer-promoter rewiring and inflammatory/activation gene induction without CTCF eviction, missing only the specific detail that SATB1 directly constrains the range of CTCF-mediated interactions at TAD boundaries.

Age-associated decay of FOXO/AMPK signaling and rising mitochondrial oxidative stress upregulate the ER–mitochondria contact-site acyltransferase ALCAT1/LCLAT1 (homologous to C. elegans ACL-3/ACL-4 and Drosophila CG17608), which actively constrains metazoan lifespan by remodeling inner mitochondrial membrane cardiolipin from symmetrical linoleoyl (18:2) chains into hyper-peroxidizable very-long-chain polyunsaturated species (20:4 and 22:6). This maladaptive trans-organellar acyl substitution overrides protective Tafazzin (TAZ)-mediated transacylation, converting cardiolipin from a structural stabilizer of respiratory supercomplexes into a pro-oxidant trigger of bioenergetic failure, mitophagy arrest, and cytosolic mtDNA-driven sterile inflammation. Mechanism: Under youthful homeostasis, newly synthesized cardiolipin is remodeled within the inner mitochondrial membrane (IMM) by the phospholipid-lysophospholipid transacylase Tafazzin (TAZ/TAZ-1) into symmetrical tetralinoleoyl-cardiolipin (TLCL, 18:24), which maintains negative cristae curvature and anchors electron transport chain (ETC) supercomplexes. During ageing, declining AMPK and FOXO/DAF-16 transcriptional repression coupled with chronic reactive oxygen species (ROS)-activated MAPK signaling induces the expression and stabilization of ALCAT1/LCLAT1 at mitochondria-associated ER membranes (MAMs). ALCAT1 intercepts monolysocardiolipin (MLCL) at ER–mitochondria contact sites and selectively esterifies it with ER-derived arachidonoyl-CoA (20:4-CoA) and docosahexaenoyl-CoA (22:6-CoA) produced by ACSL4. Because these bis-allylic-rich chains reside immediately adjacent to Complex I/III ROS-generating centers, they undergo rapid radical-mediated hydroperoxidation (CL-OOH). Oxidized PUFA-cardiolipin loses its biophysical capacity to support cristae curvature, activates cytochrome c peroxidase activity, prevents externalized cardiolipin from binding LC3 to initiate mitophagy, and induces VDAC/mPTP-dependent extrusion of oxidized mitochondrial DNA into the cytosol, activating the cGAS–STING–TBK1 innate immune senescence cascade across post-mitotic tissues. Prediction: Adult-onset genetic knockdown or pharmacological inhibition of ALCAT1/LCLAT1 (or acl-3/acl-4 in C. elegans and CG17608 in Drosophila)—or dietary supplementation with bis-allylic deuterated linoleate (d2-18:2) and arachidonate (d6-20:4) that selectively block radical-mediated hydrogen abstraction via the kinetic isotope effect without altering acyl-chain saturation—will preserve the TLCL:PUFA-cardiolipin ratio, restore mitophagic flux, suppress cytosolic mtDNA-induced cGAS–STING activation, and extend median and maximum lifespan across C. elegans, Drosophila, and aged mice. Conversely, overexpressing Tafazzin or administering general mitochondrial antioxidants without suppressing ALCAT1/LCLAT1 activity will fail to prevent ongoing PUFA-cardiolipin incorporation or rescue longevity, proving that ALCAT1-driven acyl remodeling rather than passive oxidative damage is the primary lifespan constraint.

• GPT-5.6 Solmatch score 2compatible with the reference findingplausibility 3 of 5

  It describes causal acyl-chain substitution in cardiolipin but differs from the broad Plb1-controlled lipid-chain elongation reported in the finding. ALCAT1-mediated cardiolipin remodeling and oxidative mitochondrial injury are credible, while the asserted orthology, universality across species, and specific lifespan mechanism remain speculative.

• Grok 4.7match score 3compatible with the reference findingplausibility 4 of 5

  ALCAT1 substitution of tetralinoleoyl cardiolipin with longer polyunsaturated chains captures lengthening of acyl chains as a lifespan constraint, while missing Plb1, the ratiometric whole-lipidome pattern, and chain-length dependence in favor of cardiolipin peroxidation. Mammalian ALCAT1–cardiolipin biology is credible and testable and does not rule out Plb1.

• Claude Opus 5.5match score 2compatible with the reference findingplausibility 3 of 5

  This proposes acyl remodeling toward longer PUFA chains, but only in cardiolipin, by ALCAT1, and the harm comes through peroxidation rather than chain length itself. ALCAT1 harm in mammalian disease models is supported; the worm and fly orthologs and the lifespan claims are uncertain.

Distinct HGPS vascular features segregate by compartment: medial VSMC loss and calcification require VSMC-intrinsic progerin, while intimal inflammation requires endothelial progerin, and adventitial fibrosis requires fibroblast progerin, implying limited interchangeability of cell-autonomous effects. Mechanism: Each mural lineage has a distinct transcriptional and stress response to progerin, so the same laminopathy maps onto different effector programs (apoptosis/calcification in VSMCs, adhesion/inflammation in endothelium, matrix deposition in fibroblasts). Prediction: In a panel of lineage-restricted progerin models, each pathological feature will appear only when the corresponding compartment expresses progerin, and combining compartments will additively recreate the full HGPS vascular phenotype.

• GPT-5.6 Solmatch score 4compatible with the reference findingplausibility 5 of 5

  It closely captures the central finding that distinct vascular compartments drive distinct pathologies, correctly assigning inflammation to endothelium and fibrosis to fibroblasts. It omits mutation correction and emphasizes VSMC loss and calcification rather than the reported VSMC-driven collagen accumulation.

• Claude Opus 5.5match score 4compatible with the reference findingplausibility 4 of 5

  Captures the central compartment-segregation claim with the correct assignments of inflammation to endothelium and fibrosis to fibroblasts, and SMC-intrinsic effects in the media; it adds calcification/VSMC loss and omits collagen accumulation as the specific SMC output, and says nothing about base-editing reversal. Lineage-restricted mapping of progerin effects is a credible, testable framework.

• Gemini 4 Argon (medium)match score 4compatible with the reference findingplausibility 5 of 5

  P2 captures the central finding that distinct HGPS vascular pathologies segregate by compartment—specifically assigning inflammation to endothelial cells and fibrosis/matrix dysregulation to fibroblasts—while attributing medial VSMC loss/calcification rather than collagen accumulation to VSMCs and omitting base-editing rescue. It is a rigorous, well-supported hypothesis.

Resistance to CDK4/6 inhibition is enabled by an aberrant splice isoform of a chromatin-modifying enzyme that loses its regulatory domain while retaining catalytic activity, and this isoform silences the senescence transcriptional program. Forcing expression of the full-length isoform, or blocking production of the truncated one, restores palbociclib-induced senescence. Mechanism: A splicing factor whose expression rises under prolonged CDK4/6 inhibition promotes use of an alternative exon/termination site in a histone methyltransferase or demethylase transcript. The resulting protein is mistargeted to CDKN1A/CDKN2A and SASP loci, where it deposits repressive marks that prevent the stable heterochromatin-plus-p21 state needed for arrest. Cells therefore resume cycling despite sustained RB-pathway inhibition. Prediction: Isoform-specific knockdown of the truncated transcript (antisense oligonucleotide or splice-switching ASO) with no change in total gene mRNA restores SA-β-gal positivity, p21 induction and durable arrest in resistant cells, while catalytically dead rescue of the truncated isoform does not; ChIP-seq shows loss of the repressive mark specifically at senescence loci.

• GPT-5.6 Solmatch score 2compatible with the reference findingplausibility 4 of 5a suitable alternative mechanism

  It comes closest mechanistically by invoking splicing of a histone-modifying enzyme, repression of p21 and other senescence loci, catalytic dependence, and restoration of senescence. However, it proposes a truncated isoform with altered targeting rather than exon 2 inclusion increasing SUV39H2 abundance, and it does not identify SUV39H2 or H3K9me3.

• Grok 4.7match score 3compatible with the reference findingplausibility 4 of 5

  It correctly centers a catalytically active histone-methyltransferase splice isoform that represses CDKN1A and the senescence program, with isoform blockade restoring palbociclib-induced senescence. The isoform is cast as a truncated, mistargeted enzyme rather than exon-2-driven SUV39H2 overexpression that places H3K9me3 at enhancers, which a second enzyme could still do in parallel.

• Gemini 4 Argon (medium)match score 3compatible with the reference findingplausibility 4 of 5

  It accurately identifies the core mechanism class—alternative splicing of a histone methyltransferase that deposits repressive marks at the CDKN1A (p21) and senescence loci, and whose catalytic or splice-switching inhibition restores p21 and palbociclib-induced senescence—though it misses the specific identity of SUV39H2 and frames the splice change as a domain-truncating mistargeting event rather than exon 2 inclusion driving overexpression.